



University of Zagreb

FACULTY OF SCIENCE  
DEPARTMENT OF BIOLOGY

Jasminka Krištić

**CHANGES OF IMMUNOGLOBULIN G  
GLYCOSYLATION WITH AGE**

DOCTORAL THESIS

Zagreb, 2018.



Sveučilište u Zagrebu

PRIRODOSLOVNO-MATEMATIČKI FAKULTET  
BIOLOŠKI ODSJEK

Jasminka Krištić

**PROMJENA GLIKOZILACIJE  
IMMUNOGLOBULINA G TIJEKOM  
STARENJA**

DOKTORSKI RAD

Zagreb, 2018.

The work presented in this doctoral thesis was performed at Genos Ltd., Zagreb, Croatia under the supervision of Prof. Gordan Lauc, PhD, as a part of the postgraduate doctoral programme in Biology at the Department of Biology, Faculty of Science, University of Zagreb.

Ovaj je doktorski rad izrađen u Genos d.o.o., Zagreb, Hrvatska, pod vodstvom prof. dr. sc. Gordana Lauca, u sklopu Sveučilišnog poslijediplomskog doktorskog studija Biologije pri Biološkom odsjeku Prirodoslovno-matematičkog fakulteta Sveučilišta u Zagrebu.

## Zahvale

*Najljepše se zahvaljujem svom mentoru prof. dr. sc. Gordanu Laucu koji mi je omogućio da se bavim znanosti te što nadahnjuje svojim idejama i entuzijazmom kojim priča o znanosti.*

*Toplo se zahvaljujem cijeloj ekipi s posla na ugodnoj radnoj atmosferi i suradnji na brojnim projektima.*

*Posebno hvala Tomi od kojeg sam puno naučila prvih mjeseci u Genosu.*

*Hvala Maji što rado prenosi svoje veliko znanje iz glikobiologije te na brojnim savjetima i razumijevanju.*

*Hvala Tomislavu na čitanju i lektoriranju doktorskog rada, te na lijepim manirama u ophođenju s drugima.*

*Mirni, Dajani, Ivoni i Ireni hvala na prijateljstvu.*

*Iako piše da zahvalu svedemo u akademske okvire, ne znam hoću li se ikada više imati prilike javno zahvaliti određenim osobama, pa ću zato to učiniti ovdje.*

*Ne tako davno čula sam izreku „Iza svakog uspješnog muškarca stoji njegova žena, a iza svake uspješne žene njezina majka!“. Pa ako sam ja uspješna zato što ću imati doktorat znanosti, onda iza toga svakako stoji moja mama! Mama hvala ti na svemu, svom trudu, vremenu, savjetima, što si moj “glas savjesti“. Hvala tati što nas je uvijek poticao na više i bolje. Hvala mojoj sestri i bratu na podršci i ljubavi.*

*Hvala mom suprugu Vinku koji mi je podrška u svemu što radim i koji o glikobiologiji zna puno više nego što bi jedan sveučilišni specijalist ekonomije trebao znati! Hvala mojim djevojčicama Tonki i Marini uz koje je sve istodobno i teže i lakše, ali sve ima više smisla!*

*Hvala mojim dragim prijateljicama Zrinki, Nataši, Ivani i Mirti što me prate kroz život.*

*Na kraju, zahvaljujem se dragom Bogu. „Znam da tvoja ruka životom mojim ravna i svaki korak tvoj mi pogled prati.“*

University of Zagreb  
Faculty of Science  
Department of Biology

Doctoral thesis

## **CHANGES OF IMMUNOGLOBULIN G GLYCOSYLATION WITH AGE**

JASMINKA KRIŠTIĆ

Genos Ltd.

BIOCentar, Borongajska cesta 83h, Zagreb, Croatia

In this thesis, glycosylation of immunoglobulin G (IgG) was examined in 5818 individuals ranging in age from 16 to 100 years from five different populations – four European populations and a Han Chinese population by using ultra performance liquid chromatography (UPLC) in order to provide a comprehensive overview of changes in IgG glycosylation through lifetime. The results demonstrated that glycan profiles change in a similar way through lifetime across all examined populations. Nearly all IgG glycans were significantly associated with age. Sex differences in age-related changes in IgG glycosylation were observed. The combination of several IgG glycans was able to explain from 30 to 58% of variance in chronological age, with the remaining variance in the glycans attributed to physiological parameters. Analysis of IgG glycosylation in nearly 600 mice from the Collaborative Cross cohort ranging in age from 20 to 80 weeks showed that, generally, only the level of IgG glycan with alpha-1,3-galactose changed with age.

(84 pages, 10 figures, 9 tables, 226 references, original in English)

Keywords: glycosylation, immunoglobulin G, chronological age, biological age, biomarker, humans, mice

Supervisor: Professor Gordan Lauc, PhD

Reviewers: Associate professor Olga Gornik, PhD

Professor Kristian Vlahoviček, PhD

Professor Igor Rudan, PhD

## **PROMJENA GLIKOZILACIJE IMUNOGLOBULINA G TIJEKOM STARENJA**

JASMINKA KRIŠTIĆ

Genos d.o.o.

BIOCentar, Borongajska cesta 83h, Zagreb, Hrvatska

U ovom doktorskom radu analizirana je glikozilacija imunoglobulina G (IgG) kod 5818 osoba starosti od 16 do 100 godina iz pet različitih populacija – četiri europske populacije i populacije Han Kineza, koristeći tekućinsku kromatografiju vrlo visoke djelotvornosti (UPLC), kako bi se pružio detaljan pregled promjena u glikozilaciji IgG-a tijekom starenja. Rezultati su pokazali da se glikanski profili tijekom starenja mijenjaju na sličan način u svim istraživanim populacijama. Gotovo svi IgG glikani pokazali su se povezanim s dobi. Uočene su razlike između spolova u promjenama koje se događaju s glikozilacijom IgG-a tijekom starenja. Kombinacijom nekoliko IgG glikana bilo je moguće objasniti od 30 do 58% varijacije u kronološkoj dobi, a ostatak varijacije u glikanima pripisan je fiziološkim parametrima. Analiza glikozilacije IgG-a kod gotovo 600 miševa starosti od 20 do 80 tjedana iz Collaborative Cross populacije miševa pokazala je da se, sveobuhvatno gledajući, samo razina IgG glikana koji sadrži alfa-1,3 vezanu galaktozu promijenila s dobi.

(84 stranice, 10 slika, 9 tablica, 226 literaturnih navoda, jeziki izvornika: hrvatski)

Ključne riječi: glikozilacija, imunoglobulin G, kronološka dob, biološka dob, biomarker,  
ljudi, miševi

Mentor: Prof. dr. sc. Gordan Lauc

Ocjenjivači: Izv. prof. dr. sc. Olga Gornik

Prof. dr. sc. Kristian Vlahoviček

Prof. dr. sc. Igor Rudan

# TABLE OF CONTENTS

1. INTRODUCTION .....	1
1.1 A general overview of protein glycosylation .....	2
1.2 Immunoglobulin G glycosylation .....	2
1.3 The impact of glycosylation on the structure and biological function of IgG .....	5
1.4 Changes in IgG glycosylation have been observed in many diseases .....	8
1.5 Aging .....	8
1.6 Chronological and biological age .....	9
1.7 Biomarkers of aging .....	10
1.7.1 Telomere length .....	10
1.7.2 DNA methylation .....	11
1.8 Aging in mice .....	12
1.9 Changes in IgG glycosylation with age: Studies in human populations .....	13
1.10 Changes in IgG glycosylation with age: Studies in mice .....	18
1.11 Research problem and scope of the thesis .....	19
2. Glycans are a novel biomarker of chronological and biological ages .....	20
3. Profiling IgG N-glycans as potential biomarker of chronological and biological ages ...	32
4. Profiling and genetic control of the murine immunoglobulin G glycome .....	43
5. GENERAL DISCUSSION .....	55
6. CONCLUSIONS .....	61
7. REFERENCE LIST .....	63
8. APPENDICES .....	79
9. CURRICULUM VITAE .....	82

# **1. INTRODUCTION**




## 1.1 A general overview of protein glycosylation

Glycosylation is one of the most common posttranslational modifications of proteins, through which complex sugar molecules (glycans) are covalently attached to proteins. In 1991 Apweiler et al.<sup>1</sup> estimated that more than half of all proteins are glycosylated, however, according to more recent estimates, less than one-fifth of proteins appear to be glycosylated<sup>2</sup>. Despite that, this new study on the frequency of different types of posttranslational modifications also showed that glycosylation is among the top three most common posttranslational modifications of proteins. Glycosylation greatly affects the physical properties of proteins (e.g. solubility, conformation, folding, stability, etc.) as well as biological functions of proteins<sup>3</sup>. Therefore, glycans as an essential part of many proteins have an important role in almost all physiological processes including protein folding and trafficking, cell adhesion, cell signalling, proliferation, differentiation, cell migration, cell survival, development and immunity<sup>4</sup>. Changes in glycosylation have been reported in various diseases<sup>numerous references, including</sup><sup>5–8</sup> and it has also been shown that glycans have great potential as diagnostic and prognostic biomarkers of different diseases<sup>9–11</sup>. For that reason, there are a growing number of studies which try to link changes in glycosylation of a certain protein (or group of proteins) with a certain disease and/or phenotype in order to find new potential diagnostic and prognostic biomarkers for certain diseases or conditions and to get a deeper insight into the mechanism of a specific disease itself. One of the proteins whose glycosylation has been the subject of many such studies is immunoglobulin G (IgG). One of the main reasons for this is the fact that IgG is the most abundant glycoprotein and the second most abundant protein in human plasma (albumin is the most abundant protein in human plasma, but it is not glycosylated)<sup>12</sup>. Therefore, IgG has a prerequisite to be a very good non-invasive biomarker.

## 1.2 Immunoglobulin G glycosylation


IgG antibodies are a very important component of the immune system as they protect the organism against invading pathogens. They are produced by B lymphocytes. The IgG antibody consists of two fragments - Fab and Fc (Figure 1). The Fab fragment (antigen binding fragment) is the part of the IgG molecule which specifically recognizes and binds different antigens like bacteria or viruses. The Fc fragment (crystallisable fragment) provides the effector function, which means that this fragment determines how the immune system responds or reacts to the presence of a specific antigen. Through the interaction of the IgG Fc fragment with activating or

inhibitory Fc gamma receptors (Fc $\gamma$ R), which are expressed on the majority of innate immune effector cells such as mast cells, monocytes, macrophages, natural killer cells, neutrophils, eosinophils and dendritic cells, pro-inflammatory or anti-inflammatory effector pathways can be activated<sup>13,14</sup>. Furthermore, the Fc fragment of IgG can also interact with component complement C1q<sup>13</sup> and activate the complement pathway with pro-inflammatory effects<sup>14</sup>. The Fc fragment of IgG is also involved in binding of IgG to the neonatal Fc receptor (FcRn) expressed on endothelial cells and monocytes<sup>15</sup>. The interaction of IgG with FcRn determines antibody half-life but is also potentially involved in the anti-inflammatory activity of IgG<sup>14,15</sup>. It is also known that the ability of IgG to interact with different Fc receptors or to activate complement varies depending on the IgG subclass<sup>14,16,17</sup>. In humans there are four different IgG subclasses, IgG1, IgG2, IgG3 and IgG4, which differ in the constant regions of their heavy chains and are named according to their relative abundance in plasma. In mice there are five different IgG subclasses: IgG1, IgG2a, IgG2b, IgG2c and IgG3, however, although similar in name, they are not direct homologues of the human proteins<sup>18,19</sup>.



**Figure 1. Schematic representation of immunoglobulin G (IgG).** IgG protein is composed of two heavy and two light chains. IgG protein can also be divided into two functional fragments: antigen-binding fragment (Fab) which binds antigen and crystallizable fragment (Fc) which is important for effector functions such as ADCC or complement activation. Each heavy chain of Fc fragment contains a covalently attached N-glycan to highly conserved N-glycosylation site located at position asparagine (Asn) 297. In addition, some IgG molecules can contain N-glycans in the Fab fragment (~20% of IgG molecules).

IgG contains a conserved N-glycosylation site at position asparagine (Asn) 297 on each heavy chain of the Fc fragment. In addition, around 20% of IgGs also have additional glycosylation sites in the Fab fragment<sup>20–24</sup>. All IgG glycans have a pentasaccharide core structure (consisting of two *N*-acetylglucosamines (GlcNAc) and three mannose residues) which can be additionally modified with a core fucose, a bisecting GlcNAc, one or two galactoses and one or two sialic acids (Figure 2).



**Figure 2. The composition of IgG glycans.**

More than 30 different glycan structures can be found on human IgG<sup>25</sup>. Overall, human IgG glycans are predominately biantennary structures and most of them are core-fucosylated (>90%). A bisecting GlcNAc is present in ~18% of human IgG glycans and sialic acid is found in ~25% of IgG glycans. Approximately 30% of human IgG glycans contain no galactose<sup>25</sup>. The largest and most complex IgG glycan structure is a core-fucosylated biantennary glycan with two galactoses,

two sialic acids and with bisecting GlcNAc<sup>25</sup>. Furthermore, it is known that the Fab and Fc fragment are differentially glycosylated. In comparison to Fc glycans, IgG Fab glycans are generally more highly galactosylated, sialylated and have higher level of bisecting GlcNAc. On the other hand, Fc IgG glycans are more highly core-fucosylated than IgG Fab glycans and are mostly nonsialylated (neutral) structures<sup>20,26–28</sup>.

Contrary to the protein part of the IgG molecule, the synthesis of the glycan part is not regulated by a template. Rather, glycans are synthesised by the concerted action of many different proteins, including glycosyltransferases, glycosidases, nucleotide sugar transporters, transcription factors, and many other proteins<sup>29</sup>. Additionally, the biosynthesis of glycans is influenced by various environmental factors and physiological conditions<sup>29–32</sup>. Despite the absence of a direct genetic template, a relatively high heritability of IgG glycosylation has been reported, ranging from 30% to 80%, depending on the IgG glycan<sup>25,33</sup>.

While human IgG glycosylation has been well studied, data on IgG glycosylation in mice are rather scarce and obscure. The data available in the literature show that though most glycan structures found on mouse IgG are shared between human and mouse, IgG glycosylation in mice exhibits some different characteristics from those observed in humans. Mouse and human IgG glycosylation differs with respect to the type of sialic acid present at the terminus of sugar chains attached to IgG proteins; mouse IgGs contain sugars which terminate with *N*-glycolylneuraminic (Neu5Gc) acid while human IgGs have terminal *N*-acetylneuraminic acid (Neu5Ac)<sup>34–36</sup>. Further, glycan structures with terminal alpha 1–3 bound galactose are found on mouse IgG but not on human IgG<sup>34</sup>. Also, several inconsistencies are found within the literature with regards to some specific features of mouse IgG glycosylation. Some studies reported that the level of fucosylation was higher for mouse than for human IgG and that almost all mouse IgG glycans contained core fucose<sup>35–37</sup>, while others reported that fucosylation of mouse IgG was lower than in humans<sup>38</sup>. Further, the prevailing view in the field is that mouse IgG does not have bisecting GlcNAc<sup>34–37</sup>. However, more recent evidence suggests that mouse IgG glycans may contain bisecting GlcNAc<sup>38,39</sup>.

### 1.3 The impact of glycosylation on the structure and biological function of IgG

It is well documented that IgG Fc glycosylation stabilizes the structure of the Fc fragment, which is required for binding to the Fc receptors and complement factors. Deglycosylation (i.e. the removal of glycans) of the Fc fragment results in decreased binding or complete loss of binding to

Fc $\gamma$ R or to proteins involved in the complement pathways and thus leads to an inability of IgG to elicit effector functions including complement activation, antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC)<sup>40-43</sup>. It is also well known that differences in the Fc glycosylation pattern alter the conformation of the Fc fragment which in turn modulates the binding affinities of IgG for Fc $\gamma$ R and complement factors enabling fine-tuning of the IgG Fc-mediated immune response<sup>42,44</sup>.

#### Core fucose

For example, the absence of core fucose on IgG glycans results in a stronger binding affinity of IgG to Fc gamma receptor IIIa (up to 50-fold increased binding) and leads to enhanced ADCC activity while the presence of core fucose reduces the ADCC activity of IgG<sup>45,46</sup>. Moreover, it was found that interactions between IgG Fc glycans and glycans of the Fc $\gamma$ RIIIa receptor have an effect on binding affinity between IgG and Fc $\gamma$ RIIIa where the presence of core fucose on glycans attached to Fc fragment sterically inhibited such interactions which resulted in decreased binding affinity for the receptor<sup>47</sup>.

#### Bisecting GlcNAc

The addition of bisecting GlcNAc to IgG glycans was reported to cause an increase in ADCC through higher affinity for Fc $\gamma$ RIIIa<sup>48</sup>. However, Shinkawa et al<sup>49</sup> showed that the presence of very high levels of IgG glycans with bisecting GlcNAc resulted in only a slight increase of ADCC activity and that high content of glycans lacking core fucose was more potent in enhancing ADCC when compared to bisected glycans. It is also known that the presence of bisecting GlcNAc inhibits the addition of core fucose<sup>50</sup>.

#### Sialic acid

The effector function of IgG can also be modulated by terminal sialic acid residues. Many studies have demonstrated that sialylation acts as a switch between pro-inflammatory and anti-inflammatory activity of IgG<sup>51,52</sup> (reviewed in<sup>53-55</sup>). IgG antibodies which are not sialylated stimulate pro-inflammatory immune responses through interaction with Fc $\gamma$  receptors<sup>42</sup>. On the other hand, IgGs which contain sialylated glycans exhibit anti-inflammatory properties. Moreover, several lines of evidence suggest that sialic acid residues of N-glycans attached to the IgG Fc fragment are responsible for the anti-inflammatory properties of intravenous immunoglobulin (IVIG) preparation but the exact mechanism by which sialylated IgGs exert anti-inflammatory activity is still unclear<sup>14,42,44,51-56</sup>. One of the proposed mechanisms suggests that sialylated IgGs interact with the C-type lectin receptor DC-SIGN which increases expression of

inhibitory receptor FcγRIIb and thus suppresses inflammation<sup>57-59</sup>. However, conflicting results exist regarding the involvement of DC-SIGN in the anti-inflammatory activity of sialylated IgG and some other receptors which could recognize sialic acid and trigger anti-inflammatory pathways have been proposed<sup>53</sup>. Moreover, there is also some evidence that sialic acid can act in a receptor-independent manner to activate the anti-inflammatory response and that IVIG may recruit sialic acid-independent anti-inflammatory pathways<sup>44,53,54</sup>.

#### Galactose

Karsten et al<sup>60</sup> have recently showed that galactosylated IgG also exerts anti-inflammatory activity by FcγIIB receptor- and Dectin-1-mediated inhibition of the complement pathway. On the contrary, IgG glycans which lack terminal galactose residues (agalactosylated glycans) possess the ability to interact with mannose binding lectin (MBL) and activate the lectin complement pathway<sup>61</sup>, and it has been shown that the pro-inflammatory activity of agalactosylated IgG is dependent on the presence of activating Fc receptors<sup>62</sup>. In addition, several lines of studies have demonstrated that removal of terminal galactose residues from IgG glycans significantly reduces complement-dependent cytotoxicity (CDC)<sup>63,64</sup>. IgGs containing high-mannose glycans and glycans with terminal GlcNAc residues (agalactosylated glycans) have been shown to bind to the mannose receptor (MR) which plays a potential role in antibody clearance<sup>65-68</sup>.

#### Role of glycans in activation of complement pathways

Banda et al<sup>69</sup> have reported that the alternative complement pathway can also be initiated by IgG antibodies present in the form of immune complexes (and not just by the spontaneous hydrolysis of the complement component C3) and that this process is dependent on IgG N-glycans. The same study has also shown that agalactosylated IgG activates both the classical and alternative complement pathways more efficiently than the lectin pathway.

#### Role of IgG glycans in the IgG-FcRn interaction

The neonatal receptor (FcRn) transports IgG from mother to fetus and also, throughout life, regulates the serum half-life of IgG<sup>15</sup>. Although it was thought that the interaction between IgG and the neonatal Fc receptor (FcRn) is not influenced by Fc glycosylation, recent data suggest that glycans on IgG do affect the IgG-FcRn interaction<sup>70,71</sup>.

#### Fab glycans

There is emerging evidence that Fab glycosylation has a significant impact on the functional properties of IgG. Fab glycosylation can presumably affect antigen-binding affinity, antibody half-life, antibody aggregation and immune complex formation<sup>72</sup>.

#### 1.4 Changes in IgG glycosylation have been observed in many diseases

A great number of studies reported significant changes in the composition of the IgG glycome in different diseases. Over 30 years ago, Parekh et al<sup>8</sup> reported that the IgG glycosylation profile is changed in patients with rheumatoid arthritis and since then lots of work has been done on IgG glycosylation in rheumatoid arthritis<sup>28,73-76</sup>. These subsequent studies confirmed and extended initial observations and also demonstrated that the glycosylation pattern of IgG which is associated with rheumatoid arthritis is detectable before the onset of the disease<sup>77</sup>. Moreover, following the discovery of the correlation between decreased galactosylation and occurrence of rheumatoid arthritis, changes in IgG glycosylation have been observed in numerous other inflammatory and autoimmune diseases including psoriatic arthritis<sup>78</sup>, systemic lupus erythematosus<sup>79,80</sup>, inflammatory bowel disease<sup>81,82</sup>, Hashimoto's thyroiditis<sup>83</sup>, Sjögren's syndrome<sup>73,84</sup>, Lambert-Eaton myasthenic syndrome and myasthenia gravis<sup>85</sup>. In addition, aberrant IgG glycosylation was also demonstrated in neurodegenerative diseases<sup>86-88</sup>, infectious diseases<sup>89-94</sup>, cancers<sup>95-106</sup>, periodontal disease<sup>107</sup>, small vessel vasculitis<sup>108</sup> and in many other diseases. Furthermore, it was also reported that IgG glycosylation changes in pregnancy<sup>27,109</sup>, upon vaccination and depending on the type of vaccine used (different vaccines are needed for different pathogens)<sup>110-113</sup>, after anti-TNF therapy<sup>114</sup>, after treatment with different B cell stimulants (such as all-trans retinoic acid, CpG oligodeoxynucleotide, interleukin-21, etc.)<sup>115</sup> and depending on hormonal status<sup>98,116</sup>.

#### 1.5 Aging

Aging is most commonly described as a complex and continuous process characterized by the increasing accumulation of damage and changes with time that leads to progressive functional decline, increased susceptibility to disease and ultimately, death<sup>117,118</sup>. A large body of scientific literature exists on aging and many research efforts have been made in an attempt to unravel the underlying mechanism of aging. Multiple lines of evidence have been provided suggesting the existence of multiple mechanisms of aging. Recently, nine hallmarks of aging were proposed that characterize the process of aging and define the mechanisms that contribute to the aging process<sup>118</sup>. These hallmarks are: 1) Genomic instability (accumulation of DNA damage and disruption of nuclear architecture); 2) Telomere shortening; 3) Epigenetic alterations (alterations of histone modifications, DNA methylation, chromatin remodeling and transcriptional alterations); 4) Loss of proteostasis (decline in chaperons synthesis and activity of proteolytic

systems); 5) Deregulated nutrient sensing (deregulation of the nutrient sensing pathway: insulin and insulin growth factor 1 (IGF-1)-signaling, mammalian target of rapamycin (mTOR), adenosine monophosphate-activated protein kinase (AMPK) and sirtuins); 6) Mitochondrial dysfunction (increase in reactive oxygen species (ROS) production, reduction in mitochondrial biogenesis and disruption of mitochondrial integrity); 7) Cellular senescence; 8) Stem cell exhaustions; 9) Altered intercellular communication (chronic low-grade inflammation (inflammaging)). Each of the proposed hallmarks fully or partly meets the following three criteria for designation as a hallmark of aging: 1) it should manifest during normal aging; 2) experimental aggravation should accelerate aging; 3) experimental amelioration should slow down normal aging and extend lifespan<sup>118</sup>. The hallmarks are interconnected, they co-exist and interact with each other during aging and together determine the aging phenotype<sup>118</sup>.

The genetic contribution to variation in human lifespan has been estimated to range from 15 to 30%, based on twin and population studies<sup>119</sup>. Environment and lifestyle also influence the aging process. It has been shown that various environmental factors and lifestyle choices, such as diet, physical activity, stress, smoking, radiation, air pollution and many others, can accelerate or delay the progression of aging<sup>120-125</sup>.

## 1.6 Chronological and biological age

It is known that all organ systems decline in functionality with age and that this results in age-related changes in physical appearance, as well as in changes in physical and cognitive abilities<sup>124,126</sup>. Moreover, the age-associated physiological deterioration is a major risk factor for many common diseases, such as Alzheimer's disease, diabetes, heart disease, and cancer<sup>127-129</sup>. The rates of occurrence of these and many other age-related diseases increase dramatically with age<sup>128</sup>. However, although all people age (i.e. experience age-related changes) they do not age at the same rate<sup>130-133</sup>. People of the same chronological age can vary greatly in physical appearance, disability, health status and can possess different risks for age-associated diseases, or in other words, people of the same chronological age can vary considerably in their biological age<sup>131,133-135</sup>. Chronological age is a measure of time that has passed since birth. On the other hand, biological age, which is a measure of the health status and overall physiological state of an individual, is determined by physiology rather than chronology<sup>131,134-136</sup>. The existence of large interindividual differences in the rate and extent of physiological decline associated with aging, as well as differences in susceptibility to different age-related diseases has led to a need for



biomarkers of aging that can be used to predict, monitor, and provide insight into age-related physiological decline and disease<sup>130–132,134,135,137,138</sup>. Such biomarkers could be also used to guide lifestyle changes (for individuals at high risk of age-associated morbidity and mortality) or early treatment of age-related diseases<sup>134</sup>. Furthermore, biomarkers of aging could serve to monitor and evaluate interventions that may potentially slow the progression of age-related physiological decline, prevent or delay the onset of age-related diseases and extend healthy lifespan<sup>132,134</sup>. Moreover, given the increase in the elderly population throughout the world and the accompanying rise of age-related diseases and their economic burden (i.e. increase in healthcare costs)<sup>139,140</sup>, the urgent need for effective biomarkers of aging has become even more evident<sup>131</sup>.

## 1.7 Biomarkers of aging

The American Federation for Aging Research has proposed the following criteria for a biomarker of aging: 1) it must predict rate of aging (i.e. it should tell us exactly where a person is in their total lifespan) and be a better predictor of lifespan than chronological age alone; 2) it must monitor a basic process that underlies the aging process, not the effects of disease; 3) it must be able to be tested repeatedly without harming the person (e.g. blood test or an imaging technique); 4) it must be something that works in humans and in laboratory animals, such as mice (so that it can be tested in laboratory animals before being validated in humans)<sup>141,142</sup>. To date, a very large number of potential molecular and physiological biomarkers of aging have been proposed in the literature<sup>130–132,135,143</sup>. Among all candidate biomarkers of aging, telomere length and DNA methylation are probably the best studied.

### 1.7.1 Telomere length

Telomeres are DNA-protein complexes (tandem repeats of the TTAGGG sequence and associated protective proteins) located at the ends of chromosomes that protect the genomic DNA from degradation, unnecessary recombination and interchromosomal fusion during cell division. With each round of cell division, telomeres become shorter because telomerase, the enzyme responsible for maintaining telomere length, has very low or undetectable activity in many human cell types<sup>144,145</sup>. Both cross-sectional and longitudinal studies have shown that leukocyte telomere length decreases with age, but it appears that the correlation between telomere length and chronological age is rather weak with a correlation coefficient of only around -0.3<sup>146,147</sup>. There is high interindividual variability in telomere length at birth<sup>148</sup> and among individuals of the same age<sup>149</sup>. Part of this variability is heritable<sup>149</sup> and part is determined by environmental factors<sup>150,151</sup>.

Many, but not all, studies have demonstrated that the individuals with shorter leukocyte telomere lengths have a higher mortality rate<sup>145,147,152,153</sup>. Moreover, shorter telomeres have been associated with a variety of age-related conditions and diseases, including cardiovascular disease, Alzheimer's disease, diabetes, various cancers, poor immune function and osteoporosis, although not all studies have confirmed these associations<sup>130,138,145,147,153,154</sup>. Also, telomere length has been inconsistently associated with measures of physical function, cognitive function and general health status<sup>152,153</sup>. Interindividual telomere length variability may partly explain such conflicting results<sup>152,155,156</sup>. Further, there is also evidence suggesting that telomere length and the rate of telomere shortening can reflect lifestyle habits/factors. It has been proposed that unhealthy lifestyle habits/factors such as smoking, lack of physical activity, obesity, stress, exposure to pollution, etc. can potentially increase the rate of telomere shortening, disease risk, and pace of aging. On the other hand, dietary restriction, appropriate diet and regular exercise can potentially reduce the rate of telomere shortening, disease risk, and pace of aging<sup>150,151,154,157</sup>. Mice have longer telomeres than humans and also higher telomerase activity in somatic cells, but the lifespan of mice is shorter than that of humans<sup>152,153,158-160</sup>. In addition, it seems that mouse strains with longer telomeres do not live longer than mouse strains with shorter telomeres<sup>160</sup>. However, telomere shortening with age has been observed in mice<sup>118,152,160</sup>. Furthermore, it has been shown that knocking-out telomerase in mice leads to telomere shortening, but several generations of such mice appear to be phenotypically normal. Later generations of telomerase-deficient mice show reduced lifespan and some signs of premature aging, including reduced stress response, increased genetic instability and reduced tissue regeneration<sup>152,153,160-162</sup>. Besides this, it has been shown that reactivation or overexpression of telomerase in mice can reverse or delay aging<sup>118,152,153,160</sup>.

### 1.7.2 DNA methylation

DNA methylation refers to the presence or absence of a methyl group (5-methylcytosine) at CpG dinucleotides. In the genome, CpG dinucleotides tend to come in clusters called CpG islands, which are mostly found in or near gene promoters (~5% of all CpGs in mammalian genomes). CpG islands are mainly unmethylated. However, the majority of CpG dinucleotides are dispersed throughout the genome and are predominately methylated<sup>163-165</sup>. It has been shown that DNA methylation levels of certain CpG sites in the human genome are highly correlated with chronological age<sup>131,163,164,166,167</sup>. These CpG sites either get hypermethylated or hypomethylated with age and when combined these sites can accurately predict chronological age, with a

coefficient of correlation of up to 0.97<sup>166,167</sup>. Such a biomarker of age is often called the “epigenetic clock/age” or “DNA methylation age”<sup>131,163,167,168</sup>. Moreover, it has been demonstrated that DNA methylation-based biomarkers can accurately predict age across different tissues<sup>167</sup>. Besides being able to accurately predict chronological age, DNA methylation has also been found to be a good predictor of biological age. Studies have linked DNA methylation age acceleration (residuals of the DNA methylation age estimate regressed on chronological age) and/or the difference between DNA methylation age and chronological age ( $\Delta$ age) to mortality, physical and cognitive (in)ability and age-related diseases such as cancers, Alzheimer’s disease and Parkinson's disease<sup>131,168–171</sup>. Very recently, a DNA methylation age predictor has been identified in mouse<sup>172</sup>. However, the molecular mechanism underlying age-related changes in DNA methylation and the role of these changes in aging remain to be elucidated<sup>131,163,164</sup>.

It has also been reported that telomere length and DNA methylation age estimates do not correlate to each other and that they are independent predictors of chronological age. It is therefore likely that telomeres and DNA methylation employ different aging mechanisms and describe different parts of the aging process<sup>173,174</sup>. Given the existence of multiple mechanisms of aging and also the fact that all potential biomarkers of aging reported to date have some advantages and disadvantages, it has been proposed that a combination of different biomarkers of aging might measure biological age better than any individual marker<sup>134</sup>.

## 1.8 Aging in mice

Mice are the most commonly used animal model for studying different aspects of human biology and disease (about 61% of total animals used<sup>175</sup>) due to their high level of genetic and physiological similarity to humans but also due to a number of other factors like low cost, relatively short lifespan, availability, genetic manipulability and the ability to control for environmental effects. The field of aging is not exception - the mouse has also been extensively used as an experimental animal in aging research. However, some aspects of aging are different between mice and humans. The average lifespan of laboratory mice is 1-3 years (depending on strain), whereas the average lifespan of humans is about 80 years (but this varies depending on the country)<sup>176</sup>. Several hypotheses have been proposed to explain the difference in lifespan between mice and humans, including differences in the mass-specific metabolic rate, production rate of reactive oxygen species (ROS), body size and DNA repair capacity<sup>177–180</sup>. As already mentioned earlier, mice have longer telomeres than humans and also have active telomerase enzyme in almost all their tissues<sup>159,181</sup> but their lifespan is much shorter than that of humans,

implying that telomeres are not relevant to aging in mice. Although, there is also some evidence to suggest that telomeres may be relevant to aging in mice<sup>182</sup> and also that long telomeres in mice potentially protect against age-dependent diseases such as cardiovascular disease<sup>183</sup>. Moreover, mice and humans differ in respect to age-related pathologies that they develop. For example, although quite common in elderly people, cardiovascular disease and Alzheimer's disease are rare or nonexistent in old mice<sup>125</sup>. Additionally, in mice, mesenchymal and hematopoietic cancers prevail, whereas humans predominantly suffer from epithelial cancers<sup>177</sup>. Many mouse models of aging have been developed, including premature aging mouse models, mouse models of delayed aging and mouse models of human premature aging syndromes (i.e. Werner syndrome (WS) and trichothiodystrophy (TTD))<sup>125,159</sup>. Although mouse models have proven useful for studying aging, these models also have some limitations. First, mouse models of accelerated aging and premature aging syndromes display only a few characteristics of premature aging<sup>125</sup>. Second, most aging studies in mouse models use inbred strains that might not be representative of a genetically diverse aging human population<sup>159,184</sup>. Finally, the genetic background of the strain used could affect the results of aging studies. For example, many inbred strains exhibit some strain-specific pathologies which may interfere with the studied aging phenotype<sup>184</sup>.

### **1.9 Changes in IgG glycosylation with age: Studies in human populations**

Exactly three decades ago, in 1988, Parekh et al.<sup>185</sup> reported that IgG glycosylation changes with age. By examining IgG glycosylation in a population of 151 healthy individuals of both sexes ranging in age from 1 to 70 years, they observed a decrease in agalactosylated (lacking galactose) glycans until the age of approximately 25 years, and afterwards an increase in the same group of glycans with age, while age-related changes of digalactosylated glycans were inverse to those observed for agalactosylated glycans. They also noted that the level of monogalactosylated glycans remained constant with age. However, they found no significant differences between the sexes in the galactosylation of IgG. Studies following this initial observation further confirmed the reported association between a change in IgG galactosylation and age, but some new links between IgG glycans and age were also established. In a subsequent study on 112 healthy individuals of both sexes (20-70 years old) the age-related increase in agalactosylated IgG glycans was confirmed for both sexes<sup>186</sup>. In addition, the study also reported that male individuals showed slightly higher levels of IgG agalactosylation than females of the same age. In a study published several years later, in 1997<sup>187</sup>, IgG glycosylation was analyzed in 176 female and 227 male individuals (403 individuals in total) varying in age from 0 to 85 years. It was found that not

only galactosylated glycans but also bisecting GlcNAc containing glycans display age-dependent changes; both agalactosylated glycans and bisecting GlcNAc-containing glycans were shown to increase with increasing age. It was also observed that the level of agalactosylated glycans correlated with age better in females ( $r_s=0.666$ ) than in males ( $r_s=0.327$ ). Moreover, a difference in the level of agalactosylated IgG glycans between males and females in their twenties was reported; the level of agalactosylated glycans was found to be lower in females than in males (similar to what had been reported previously by Tsuchiya et al.<sup>186</sup>). A year later, Shikata et al.<sup>188</sup> published a study that investigated the glycosylation of IgG in a small cohort consisting of 43 female and 37 male healthy individuals ranging in age from 18 to 73 years. In a slight contrast to previous studies, a significant age-dependant increase in agalactosylated glycans and corresponding decrease in digalactosylated glycans were observed in females only. This inconsistency with previous studies could have arisen due to the small sample size of the study (only 37 male individuals) and consequent low statistical power. In female individuals a decrease in the level of monosialylated glycans with age was also reported. However, the level of IgG glycans with bisecting GlcNAc was found to increase with age in both sexes and this finding was consistent with that of a previous study by Yamada et al.<sup>187</sup>, while, on the other hand, the levels of disialylated, monogalactosylated, or fucosylated IgG glycans did not change with age neither in males or females. In a more recent study, the age-dependent changes in IgG glycans were evaluated in a small sample of 62 individuals of both sexes aged between 22 and 79 years<sup>189</sup>. Consistent with earlier findings, results from this study demonstrated that the abundance of agalactosylated glycans increased with increasing age, while the abundance of digalactosylated glycans, as well as the abundance of monosialylated digalactosylated glycans, decreased with age. Additionally, in accordance with previous studies, the level of bisecting GlcNAc increased with age.

Furthermore, four studies with large simple sizes have explored the association between IgG glycans and age and they used different high-throughput methods to analyse IgG glycosylation. In the first of these studies published in 2010<sup>190</sup>, the glycosylation of IgG was analysed in 1287 offspring of long-lived siblings and in 680 partners of the offspring (age 30-79 years) from the Leiden Longevity Study. Six different IgG glycans were quantified by using MALDI-TOF (*Matrix-Assisted Laser Desorption Ionization-Time of Flight*) mass spectrometry analysis, which included two agalactosylated core fucosylated biantennary glycans (with and without bisecting GlcNAc), two monogalactosylated core fucosylated biantennary glycans (with and without bisecting GlcNAc) and two digalactosylated core fucosylated biantennary glycans (with and

without bisecting GlcNAc), and the relationship between each of these six glycans and age was explored. This study confirmed the previously reported age-related increase in agalactosylated glycan structures (with and without bisecting GlcNAc) and decrease in digalactosylated glycan structures (with and without bisecting GlcNAc). In addition, sex-related differences were observed at ages below 60 years. The level of agalactosylated glycans was lower in younger females (ages <60 years) than in males, but females also showed a more pronounced increase in agalactosylated glycans with increasing age, resulting in similar galactosylation for both sexes above the age of 60. It was also found that the ratio of presence to absence of bisecting GlcNAc in digalactosylated structures tended to increase with increasing age. Interestingly, in the same study, the authors also observed that at ages below 60, the offspring of nonagenarian siblings (who were assumed to have a higher susceptibility to become long-lived) had a lower level of agalactosylated core fucosylated biantennary glycan with a bisecting GlcNAc when compared to the partners of the offspring (who represented the general population and served as control subjects), indicating the potential of bisecting GlcNAc-containing agalactosylated glycan from human IgG as an early biomarker of human longevity. Moreover, given that the offspring were previously observed to be healthier than their partners (they showed lower prevalence of myocardial infarction, hypertension and diabetes mellitus)<sup>191</sup>, the authors speculated about the possibility that the lower level of agalactosylated glycan with bisecting GlcNAc (compared to the average level of the same glycans observed in the general population) could be an indicator of better health status, thus raising the interesting possibility that this IgG glycans could be used as a biomarker of healthy aging. In the second of four large-scale studies published in 2011<sup>25</sup>, the association of IgG glycosylation and age was investigated in a total of 2298 individuals of both sexes (age 18–100 years) from three isolated populations (from the Croatian island of Vis, the Croatian island of Korčula and the Northern Scottish Orkney Islands) using hydrophilic interaction liquid chromatography (HILIC). A strong association between the level of IgG galactosylation and age was observed (age explained 35% of the variance of agalactosylated glycans). In addition, an increase in bisecting GlcNAc content and a decrease in sialylation of IgG glycans were observed with increasing age, while core fucosylation of IgG did not change with age. However, this study did not examine age-related changes in IgG glycosylation in a sex-specific manner. In the third large-scale study published in 2012<sup>98</sup>, the age-related changes in IgG glycosylation were analysed in a cohort of 735 healthy Chinese individuals of both sexes (6-70 years old) using MALDI-FTICR (*Matrix-Assisted Laser Desorption Ionization-Fourier-Transform Ion Cyclotron Resonance*) mass spectrometry analysis. Fourteen individual IgG glycans and seven IgG glycosylation features (i.e. galactosylation, agalactosylation,

monogalactosylation, digalactosylation, bisecting GlcNAc, afucosylation and sialylation) were measured. Although many findings of this study were in accordance with previous studies (i.e. increase in agalactosylated and decrease in digalactosylated glycans with increasing age), there were also some new observations, especially those related to sex-specific differences in the pattern of age-related changes in IgG glycosylation, which had not been reported previously. It was found that in males the level of agalactosylated glycans began to increase in twenties, whereas in females the level of agalactosylated glycans began to increase after midlife. In addition, at ages around the twenties and midlife females exhibited a lower level of agalactosylated glycans and a higher level of galactosylated glycans than males, while around the age of 70 years the situation was reversed (i.e. levels of galactosylated glycans were lower and levels of agalactosylated glycans were higher in females than in males). Interestingly, females showed more dramatic changes in glycosylation during lifetime than males, which were especially visible between the ages of 18 to 24 and 43 to 48 years, the two age ranges which coincide with the end of puberty and the onset of menopause, respectively. In the fourth study published in 2013<sup>192</sup>, the glycosylation of IgG was investigated by MALDI-TOF mass spectrometry in 1709 individuals of both sexes (age 18-98 years) from the Croatian island of Vis and Korčula (these two population-based cohorts were also used in the large-scale study published in 2011<sup>25</sup>). Changes in levels of individual IgG glycans as a function of age were not explored; rather, this study focused on changes in four IgG glycosylation features, including sialylation, galactosylation, core fucosylation and the occurrence of bisecting GlcNAc, with respect to age. This study corroborated and extended the findings from the large-scale study published in 2012<sup>98</sup>. The main findings of this study were that the age-related glycosylation changes in all examined glycosylation features were more pronounced in younger individuals (<57 years) than in older individuals (>57 years) and in females than in males. More specifically, in agreement with previous studies<sup>98</sup>, galactosylation and sialylation decreased with increasing age in both sexes and the most prominent decrease in the levels of both galactosylation and sialylation in females was observed around the age of 45 to 60 years, when females usually enter menopause. Furthermore, females showed higher levels of galactosylation and sialylation at younger age while males showed slightly higher levels at older age. The incidence of bisecting GlcNAc was found to increase with age but, interestingly, reached a plateau at older age. Additionally, the level of IgG core fucosylation decreased very slightly with increasing age but such association between core fucosylation and age was observed only in younger individuals. No sex differences were found for the bisecting GlcNAc and core fucosylation.

Very few studies have examined age-dependent changes in IgG glycosylation in children and adolescents, mainly because of difficulties in recruiting sufficient numbers of children and adolescents, and especially healthy children and adolescents. As already mentioned above, the study by Parekh et al.<sup>185</sup> was the first to examine changes in IgG glycosylation with age in a cohort that consisted of both children and adults. The study found differences in the direction of age-related changes in IgG glycans between children and adults. In children agalactosylated glycans decreased with age while digalactosylated glycans increased with age and the opposite effect was observed in adults (i.e. agalactosylated glycans increased with age while digalactosylated glycans decreased with age). Successively, in a study on 164 healthy children and adolescents between 6 and 18 years of age (96 girls and 68 boys with a median age of 13 years), a decrease in the level of agalactosylated and core-fucosylated IgG glycans and an increase in the level of digalactosylated IgG glycans with age was reported<sup>193</sup>, but only in girls, thus partially confirming the initial observation by Parekh et al.<sup>185</sup>. In boys, an increase in the incidence of bisecting GlcNAc in sialylated core-fucosylated structures with age was observed. In addition, this study revealed numerous differences in IgG glycans between girls and boys, especially at the onset of puberty. Another study on 609 children between 3 and 11 years of age (288 girls and 321 boys with a median age of 8 years) confirmed the previously reported age-dependent decrease in agalactosylated and increase in digalactosylated glycans, but also reported an age-dependent increase in monogalactosylated glycans and in glycans containing bisecting GlcNAc and a decrease in the level of core fucosylation and sialylation<sup>194</sup>. However, in disagreement with previous studies which demonstrated a tendency toward an age-dependent increase of galactosylation levels in children, one study of children and adolescents ranging in age from birth to 17 years (n=90, 44 girls and 46 boys) showed that galactosylation remained relatively constant throughout childhood and adolescence<sup>195</sup>. The same study also observed a decrease in fucosylation and sialylation and an increase in bisection between birth and 17 years of age, which were in accordance with the findings of previous studies.

A number of studies have investigated changes in the abundance of different glycan structures with age in total plasma or serum proteins instead of on individual proteins like IgG<sup>31,32,196–200</sup>. Two such studies from the same group found that individuals with premature aging syndromes (i.e. Werner syndrome and Cockayne syndrome) exhibited different a glycosylation pattern compared with that observed in age-matched controls, but which was rather comparable with the glycosylation pattern observed in very elderly (90 years and above)<sup>199,200</sup>. In addition, the same group of investigators reported that patients with dementia displayed the same glycosylation



features as individuals older than their respective controls, implying that glycans could be better than chronological age for estimating the biological age of an individual, and therefore could be used as an aging biomarker. Another study which analyzed glycans from total plasma proteins reported that increased body fat and blood pressure were associated with an increase in agalactosylated and a decrease in digalactosylated glycans and the same glycans were also shown to change with age; agalactosylated glycans increased and digalactosylated decreased with age<sup>31</sup>. Furthermore, in a more recent study which analyzed glycans derived from total plasma proteins, two glycan features were found to be associated with longevity, some indicators of overall health status (such as BMI, cholesterol and CRP) and also with incidence of myocardial infarction<sup>198</sup>. Therefore, studies on glycans from total plasma proteins have not only demonstrated that glycans undergo significant changes with age but also according to these studies it seems that based on glycans it is possible to distinguish between healthy and unhealthy aging. However, given that these observations were made on total plasma glycans which actually represent the sum of glycans which originate from many different plasma proteins, it is not clear whether these observations can also be applicable to IgG glycans.

Furthermore, changes in IgG glycans have been observed in many age-related diseases, including type 2 diabetes<sup>201</sup>, Alzheimer's disease<sup>86</sup> and several types of cancer including lung<sup>97</sup>, colorectal<sup>105</sup> and prostate cancer<sup>100</sup>. In general, when compared to healthy individuals of the same age, patients with age-related disease showed increased level of agalactosylated glycans and decreased level of digalactosylated glycans. The same pattern of change in IgG glycans, as observed in patients suffering from age-related diseases, has been reported previously to also occur with increasing age.

### **1.10 Changes in IgG glycosylation with age: Studies in mice**

Only a few studies exist in the literature that have investigated changes in IgG glycosylation with age in mice. In a study conducted by Bodman et al.<sup>202</sup> seven different mouse strains were assessed at six distinct ages (2, 3, 4, 5, 6 and 8 months) for age-related changes in agalactosylated IgG glycans. An increase in the level of agalactosylated IgG glycans with age in six out of seven mouse strains was found. Another study examined age-related changes in glycosylation of total serum proteins in C57BL/6 mice aged between 3 and 25 months<sup>203</sup>. Levels of three glycans in total serum and in immunoglobulin (Ig)-depleted serum were found to change with increasing age: levels of agalactosylated and digalactosylated core-fucosylated biantennary glycans

increased with age, while level of digalactosylated bianatenary glycans decreased. However, this same study did not examine age-related changes in glycosylation of the immunoglobulin (Ig) fraction.

### **1.11 Research problem and scope of the thesis**

Based on the previous studies, indications exist that glycosylation of IgG changes with age and that IgG glycans could be used to evaluate overall age-related health status. However, previous studies that investigated glycosylation changes with age were characterized by several important limitations. First, most of the studies had relatively small sample sizes, meaning that the obtained results may not reflect a true effect<sup>204,205</sup>. It is only relatively recently that the high-throughput methods for analysis of IgG glycosylation have been developed that enable analysis of large number of samples in a short period of time. These methods include mass spectrometry (MS), capillary electrophoresis (CE) and liquid chromatography (LC)<sup>206</sup>. Second, many of the previous studies were performed on total plasma glycans (i.e. glycans that originate from all plasma proteins and not only from IgG), thus, in addition to changes in glycosylation of only one, some or all of the plasma proteins, the observed differences reflected changes in the abundance of individual plasma proteins. Additionally, there were also studies that did not cover the entire adult lifespan and those that did not examine the factor of sex in the patterns of changes in IgG glycosylation with age. Furthermore, some previous studies investigated the age-related changes of only a few, most highly abundant, individual IgG glycans while other studies focused only on changes in specific glycosylation features shared by many individual IgG glycans such as galactosylation, sialylation, core fucosylation, etc. There were also inconsistencies between studies and also some isolated observations reported in only one of the studies but not in others.

In this thesis and the presented scientific papers we sought to perform a detailed analysis of changes in IgG glycosylation with age on a large number of individuals, over the entire adult life span and in several different populations. We also investigated changes in IgG glycosylation with age on an animal model. Finally, we aimed to explore the potential of glycans to be used as biomarkers of chronological and biological age.

## **2. Glycans are a novel biomarker of chronological and biological ages**

Krištić Jasminka; Vučković Frano; Menni Cristina; Klarić Lucija; Keser Toma; Bečeheli Ivona; Pučić-Baković Maja; Novokmet Mislav; Mangino Massimo; Thaqi Kujtim; Rudan Pavao; Novokmet Natalija; Šarac Jelena; Missoni Saša; Kolčić Ivana; Polašek Ozren; Rudan Igor; Campbell Harry; Hayward Caroline; Aulchenko Yurii; Valdes Ana; Wilson James F.; Gornik Olga; Primorac Dragan; Zoldoš Vlatka; Spector Tim; Lauc Gordan.

*The Journals of Gerontology. Series A, Biological sciences and medical sciences*, 2014, 69(7):779-89.

### **3. Profiling IgG N-glycans as potential biomarker of chronological and biological ages**

A community-based study in a Han Chinese population

Yu Xinwei; Wang Youxin; Krištić Jasminka; Dong Jing; Chu Xi; Ge Siqi; Wang Hao; Fang Honghong; Gao Qing; Liu Di; Zhao Zhongyao; Peng Hongli; Pučić Bakovic Maja; Wu Lijuan; Song Manshu; Rudan Igor; Campbell Harry; Lauc Gordan; Wang Wei.

*Medicine (Baltimore)*, 2016, 95(28):e4112.

## **4. Profiling and genetic control of the murine immunoglobulin G glycome**

Krištić Jasminka; Zaytseva Olga O.; Ram Ramesh; Nguyen Quang; Novokmet Mislav; Vučković Frano; Vilaj Marija; Trbojević-Akmačić Irena; Pezer Marija; Davern Kathleen M.; Morahan Grant; Lauc Gordan.

*Nature Chemical Biology*, 2018, 14(5):516-524.

## **5. GENERAL DISCUSSION**

Glycosylation significantly affects structural and functional properties of immunoglobulin G (IgG), with multiple effects on the immune system<sup>207,208</sup>. In addition, numerous studies reported significant changes in the composition of the IgG glycome in different diseases<sup>7,208</sup>. These and other findings and observations in the field have pointed out that examination of glycosylation is of great interest in understanding the biology of IgG molecule, regulation of immune response and in understanding how changes in IgG glycosylation are linked to other processes in body in both physiological and pathological states. Characterization of IgG glycosylation in individuals from the general population is very useful as it forms a basis for all future studies on IgG glycosylation. Information about the variability of IgG glycosylation in the general population, and its dependency on age and sex is highly desirable and even indispensable.

We analyzed IgG glycosylation in almost 6000 individuals from five different populations (four European populations and a Han Chinese population) with a very broad range of ages (from 16 to 100 years) which allowed us to gain a better understanding of the relationship between glycosylation of IgG and age. The levels of nearly all IgG glycans were found to significantly change with age. With increasing age the following changes were most pronounced: 1) an increase in levels of agalactosylated core-fucosylated biantennary glycans (with and without bisecting GlcNAc), 2) a decrease in levels of digalactosylated core-fucosylated biantennary glycans (with and without bisecting GlcNAc), and 3) a decrease in the level of monosialylated digalactosylated core-fucosylated biantennary glycan without bisecting GlcNAc. These observations can be summarized as an increase in levels of agalactosylation and a decrease in levels of digalactosylation and sialylation with increasing age and they are consistent with previous findings<sup>185,187</sup>. Interestingly, although slight differences in age-related IgG glycosylation changes between different populations were observed, overall patterns of changes in IgG glycans with age were very similar among all examined populations. This may imply the existence of a universal principle of changes in IgG glycosylation with age, regardless of population. In addition, our findings demonstrate that age and sex interact, so that glycosylation changes with age are more prominent in females than in males. In particular, we found that, in women, the most dramatic change in IgG glycosylation occurred between the ages of 40 and 60 years, which coincides with the menopause transition, a period characterized by hormonal changes. Interestingly, not only do hormones modulate IgG glycosylation<sup>209</sup>, but sex differences in hormonal status have been proposed as a possible explanation for sex differences in lifespan<sup>210</sup>. This indicates that the relationship between age, sex, hormonal status and changes in IgG glycosylation is quite complex as these factors are obviously not independent of each other.

The exact molecular mechanisms that underlie age-related changes in IgG glycosylation are not currently known. However, the consistency of changes between different populations, points to a tight regulation of age-related changes in IgG glycosylation. Several mechanisms have been proposed that may lead to age-related changes in IgG glycosylation. It has been suggested that a decrease in IgG galactosylation (and an increase in IgG agalactosylation) with age may be explained by a decrease in the expression and/or activity of beta-1,4-galactosyltransferase (B4GALT) enzyme that adds galactose to glycans<sup>185,200</sup>. However, the expression level and/or activity of galactosyltransferase in B lymphocytes have not been examined in the general population across a wide age range and correlated with glycan levels. Recently, one study measured the activity of galactosyltransferase in the plasma of 125 individuals ranging in age from 5 to 105 years<sup>211</sup> and reported an increase in plasmatic galactosyltransferase activity with age but the level of enzyme activity did not correlate positively with the level of IgG galactosylation. The expression (mRNA and protein level) and enzyme activity of galactosyltransferase have been examined in B lymphocytes of rheumatoid arthritis patients and healthy controls<sup>212-216</sup>, cell culture systems<sup>217</sup> and in mouse models<sup>214</sup>. These studies yielded conflicting results, with some studies finding a negative relationship between the expression and/or activity of galactosyltransferase and levels of agalactosylated glycans<sup>216,217</sup>, while others found no relationships<sup>212-215</sup>. Furthermore, it has been suggested that the beta-galactosidase enzyme, that removes galactose from glycans, may also be responsible for age-related changes in IgG glycosylation<sup>196,200</sup>. It has also been proposed that age-related changes in IgG glycosylation might result from expansion of specific clones of B lymphocytes<sup>185,218</sup>.

It is still unknown what purpose these age-related changes in IgG glycosylation serve. Agalactosylated glycans enable IgG to activate pro-inflammatory effector pathways through interaction with the mannose binding lectin (MBL)<sup>61</sup> and Fcγ receptors<sup>62</sup>. On the other hand, galactosylated glycans enable IgG to exert anti-inflammatory activity through promotion of association between FcγRIIB and Dectin-1<sup>60</sup>. This suggests that IgG glycosylation changes that occur with aging (i.e. an increase in agalactosylated glycans and corresponding decrease in digalactosylated glycans) would promote inflammation. A low-grade systemic chronic inflammatory status, called “inflammaging”, has been recognized as a hallmark of aging and is characterized by increased levels of pro-inflammatory molecules<sup>118,219</sup>. This age-related increase in pro-inflammatory status is suggested to be driven by lifelong antigenic load (e.g. microbial infections, damaged macromolecules and cells, changes in gut microbiota), age-related deregulation of the immune system (immunosenescence) and by numerous other factors such as



production of reactive oxygen species (ROS) and accumulation of senescent cells<sup>121,220-222</sup>. Chronic inflammation can contribute to the aging phenotype through promotion of tissue damage<sup>220,221</sup> and is considered to be implicated in many age-related diseases<sup>121,221</sup>. Thus, age-related changes in IgG glycosylation may represent an important contributor to the initiation and/or maintenance of chronic inflammation associated with aging, as suggested by Dall'Olio et al.<sup>223</sup>. However, although the evidence suggests the existence of a relationship between glycosylation changes, chronic inflammation and aging<sup>222,223</sup>, the direction of a cause-and-effect relationship remains unclear. It is very likely that there is no simple cause-and-effect relationship, rather, that there is a complex interplay between all these factors.

The ability to accurately predict chronological age is very useful, especially in fields such as forensics. Our results demonstrate that IgG glycans are able to predict chronological age with correlation coefficients between the age predicted by IgG glycans and the chronological age ranging from 0.56 and 0.76 and an error of 9.7 years or higher depending on the population and number of glycans included in the prediction model. Although the precision of chronological age predictions based on glycans is rather moderate, and surely not precise enough for forensic purposes, it appears that glycans are more precise in the estimation of chronological age than telomere length which demonstrates correlation coefficient of around -0.3<sup>147</sup>. On the other hand, DNA methylation is probably the most accurate known predictor of chronological age with correlations between chronological age and predicted age higher than 0.9 and reported errors lower than 5 years<sup>166,167,224</sup>.

Biological age often differs from chronological age. It is known that individuals of the same chronological age vary in their health and physiological status. We have shown that the difference between the age predicted by IgG glycans and the true chronological age (i.e. according to their IgG glycans some individuals were predicted to be younger or older than their chronological age and also, some individuals showed larger deviation from chronological age than others) can, at least partly, be attributed to differences in biochemical and physiological parameters (e.g. lung function parameters, blood pressure, BMI, triglycerides and lipoproteins). Therefore, it appears that the age that is estimated based on IgG glycans to some extent reflects an individual's general health status. Future studies, in particular longitudinal studies, are needed to confirm the potential of glycans to be used as a biomarker of biological age. In particular, studies should determine whether changes in IgG glycans are modifiable (i.e. can they be slowed or reversed by interventions such as dietary changes or physical exercise), and also whether the rate of change in IgG glycans could be used to monitor health status and to predict age-related diseases.

Mice are the most commonly used animal model for studying different aspects of human biology, including protein glycosylation. In this thesis we have also examined IgG glycosylation in 589 mice from the Collaborative Cross (CC) cohort. The CC mouse population is derived from eight founder strains (five classical inbred strains and three wild-derived strains) and closely resembles genetic and phenotypic variability observed in human populations<sup>225,226</sup>. By analyzing IgG glycosylation in 95 different CC strains ranging in age from 20 to 80 weeks (most of the studied mice were in this age range) we found that the level of only one mouse IgG glycan changed with age. Interestingly, this glycan contains alpha-1,3-galactose that is not present in human IgG. To the best of our knowledge, only one prior study<sup>202</sup> has investigated changes in IgG glycosylation with age in mice. The study analyzed levels of agalactosylated IgG glycans in seven strains of mice ranging in age from 2 to 8 months and it reported that levels of agalactosylated glycans (in six out of seven strains of mice) increased with age, thus confirming observations from human studies. On the contrary, we did not find a strong general trend toward a change in the level of agalactosylated glycans with age in the CC strains. This inconsistency may be due to: 1) differences in the age range that was covered (from 2 to 8 months in the study by Bodman et al. and from 20 to 80 weeks (which corresponds to approximately 5 to 20 months) in our study, and/or 2) possible differences in the antigenic and physical environmental conditions (for example, it is not clear whether in the study by Bodman et al.<sup>202</sup> mice were kept in a specific pathogen-free environment, as were mice in our study). If the latter is true, then this would strongly support the “inflammaging hypothesis” which attributes to lifelong antigenic load the continuous increase of inflammation with age and consequential tissue damage that leads to health deterioration<sup>220,223</sup>. Future studies could explore the effects of antigenic challenge and/or different environmental factors on changes in IgG glycosylation during the lifetime of the mice.

In the end, it is worth discussing whether IgG glycans fulfill the aging biomarker criteria suggested by the American Federation for Aging Research<sup>141,142</sup>. The first criterion has been defined as follows: It must predict rate of aging and be a better predictor of lifespan than chronological age alone. Given our observation that levels of IgG glycans exhibit strong correlations with physiological parameters used in the assessment of the individual’s health status and that IgG glycan levels are associated with mortality (our unpublished data), it is highly probable that IgG glycans meet the first criterion for biomarkers of aging. The second criterion has been defined as follows: It must monitor a basic process that underlies the aging process. Given our observation that individuals from different populations follow the same pattern of change in IgG glycosylation through lifetime and the possible role of IgG glycans in the chronic

inflammation associated with aging-“inflammaging”, it is highly probable that IgG glycans also meet the second criterion for biomarkers of aging. The third criterion has been defined as follows: It must be able to be tested repeatedly without harming the person. IgG glycans are commonly analyzed in plasma or serum samples, thus, as glycan testing is minimally invasive, IgG glycans meet the third criterion for biomarkers of aging. The fourth criterion has been defined as follows: It must be something that works in humans and in laboratory animals. Since, as described in the previous paragraph, the only two studies (the study by Bodman et al.<sup>202</sup> and our study) that have examined changes in IgG glycosylation with age to date have reported conflicting results regarding whether or not the levels of agalactosylated glycans change with age, future studies are necessary for addressing the fourth criterion. Taken together, it seems that IgG glycans have great potential as biomarkers of aging, either individually or in combination with other biomarkers of aging.

## **6. CONCLUSIONS**

This thesis provides detailed information on the changes in IgG glycosylation through lifetime.

By examining IgG glycosylation in 5818 individuals from five different populations (four European populations and a Han Chinese population) with a very broad range of ages (from 16 to 100 years) we found that:

- The levels of all IgG glycans showed a significant association with age. The strongest association with age was observed in the level of galactosylation. IgG glycans that lack galactose (agalactosylated glycans) increased with age, whereas IgG glycans that contain two galactoses (digalactosylated glycans) decreased with age. Among other IgG glycans, the level of monosialylated digalactosylated core-fucosylated biantennary glycan also showed a strong association with age and its level decreased with age. These findings suggest that age-related changes in IgG glycosylation would increase the pro-inflammatory effector function of immunoglobulin G.
- All examined populations exhibited similar patterns of changes in IgG glycosylation with age.
- Men and women showed differences in the patterns of age-related changes in IgG glycosylation. Women exhibited more pronounced changes in IgG glycosylation with age than males, and especially between the ages of 40 and 60 years, an age range that coincides with menopause transition.
- The combination of several IgG glycans was able to explain from 30 to 58% of the variation in chronological age, depending on the population and number of IgG glycans included in the model. After accounting for chronological age, the remaining variation in IgG glycans was shown to be associated with differences in physiological parameters associated with biological age. Therefore, IgG glycans have the potential to be used as a biomarker of chronological and biological ages.

By examining changes in IgG glycosylation with age in nearly 600 mice belonging to 95 different Collaborative Cross strains and ranging in age from 20 to 80 weeks we found that only the level of IgG glycan containing alpha-1,3-galactose showed a significant association with age. Agalactosylated glycans did not show a general tendency to increase with age in mice.

## **7. REFERENCE LIST**

1. Apweiler, R., Hermjakob, H. & Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. *Biochim. Biophys. Acta - Gen. Subj.* **1473**, 4–8 (1999).
2. Khoury, G. A., Baliban, R. C. & Floudas, C. A. Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. *Sci. Rep.* **1**, 90 (2011).
3. Varki, A. Biological roles of oligosaccharides- all of the theories are correct. *Glycobiology* **3**, 97–130 (1993).
4. Ohtsubo, K. & Marth, J. D. Glycosylation in Cellular Mechanisms of Health and Disease. *Cell* **126**, 855–867 (2006).
5. Dube, D. H. & Bertozzi, C. R. Glycans in cancer and inflammation--potential for therapeutics and diagnostics. *Nat. Rev. Drug Discov.* **4**, 477–488 (2005).
6. Gornik, O. & Lauc, G. Glycosylation of serum proteins in inflammatory diseases. *Dis. Markers* **25**, 267–278 (2008).
7. Lauc, G., Pezer, M., Rudan, I. & Campbell, H. Mechanisms of disease: The human N-glycome. *Biochim. Biophys. Acta - Gen. Subj.* **1860**, 1574–1582 (2016).
8. Parekh, R. B. *et al.* Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. *Nature.* **316**, 452–457 (1985).
9. Adamczyk, B., Tharmalingam, T. & Rudd, P. M. Glycans as cancer biomarkers. *Biochim. Biophys. Acta - Gen. Subj.* **1820**, 1347–1353 (2012).
10. Lebrilla, C. B. & An, H. J. The prospects of glycan biomarkers for the diagnosis of diseases. *Mol. Biosyst.* **5**, 17–20 (2009).
11. Thanabalasingham, G. *et al.* Mutations in HNF1A result in marked alterations of plasma glycan profile. *Diabetes* **62**, 1329–1337 (2013).
12. Clerc, F. *et al.* Human plasma protein N-glycosylation. *Glycoconj. J.* **33**, 309–43 (2016).
13. Irani, V. *et al.* Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. *Mol. Immunol.* **67**, 171–182 (2015).
14. Lux, a, Aschermann, S., Biburger, M. & Nimmerjahn, F. The pro and anti-inflammatory activities of immunoglobulin G. *Ann. Rheum. Dis.* **69 Suppl 1**, i92–i96 (2010).
15. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. *Nat. Rev. Immunol.* **7**, 715–25 (2007).
16. Bruhns, P. *et al.* Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. *Blood* **113**, 3716–3725 (2009).

17. Lux, A., Yu, X., Scanlan, C. N. & Nimmerjahn, F. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. *J. Immunol.* **190**, 4315–23 (2013).
18. Mestas, J. & Hughes, C. C. W. Of mice and not men: differences between mouse and human immunology. *J. Immunol.* **172**, 2731–2738 (2004).
19. Zhang, Z., Goldschmidt, T. & Salter, H. Possible allelic structure of IgG2a and IgG2c in mice. *Mol. Immunol.* **50**, 169–171 (2012).
20. Holland, M. *et al.* Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. *Biochim. Biophys. Acta - Gen. Subj.* **1760**, 669–677 (2006).
21. Huang, L., Biolsi, S., Bales, K. R. & Kuchibhotla, U. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. *Anal. Biochem.* **349**, 197–207 (2006).
22. Jefferis, R. Glycosylation of Recombinant Antibody Therapeutics. *Biotechnol Prog.* **21**, 11–16 (2005).
23. Lim, A., Reed-Bogan, A. & Harmon, B. J. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer. *Anal. Biochem.* **375**, 163–172 (2008).
24. Taniguchi, T., Mizuochi, T., Beale, M., Dwek, R. A. & Rademacher, T. W. Structures of the Sugar Chains of Rabbit Immunoglobulin G : Occurrence of Asparagine-Linked Sugar Chains in Fab Fragment. *Biochemistry.* **24**, 5551–5557 (1985).
25. Pucic, M. *et al.* High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. *Mol Cell Proteomics.* **10**, M111.010090 (2011).
26. Abel, C. A., Spiegelberg, H. L. & Grey, H. M. Carbohydrate content of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. *Biochemistry* **7**, 1271–1278 (1968).
27. Bondt, A. *et al.* Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. *Mol. Cell. Proteomics* **13**, 3029–39 (2014).
28. Youngs, A., Chang, S. C., Dwek, R. A. & Scragg, I. G. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. *Biochem J* **314**, 621–630 (1996).
29. Krištić, J., Zoldoš, V., and Lauc, G. in *Glycoscience: Biology and Medicine* (ed. Endo, T., Seeberger, P. H., Hart, G. W., Wong, C.-H., and Taniguchi, N.) 1–7 (Springer Japan, 2014).
30. Lauc, G. & Zoldoš, V. Protein glycosylation — an evolutionary crossroad between genes and environment. *Mol Biosyst.* **6**, 2373–2379 (2010).



31. Knežević, A., Gornik, O., Polašek, O., Pu, M. & Redži, I. Effects of aging , body mass index , plasma lipid profiles , and smoking on human plasma N-glycans. *Glycobiology*. **20**, 959–969 (2010).
32. Knezevic, A. *et al.* Variability , Heritability and Environmental Determinants of Human Plasma N-Glycome research articles. *J Proteome Res*. **8**, 694–701 (2009).
33. Menni, C. *et al.* Glycosylation of immunoglobulin G: Role of genetic and epigenetic influences. *PLoS ONE*. **8**, 6–13 (2013).
34. Blomme, B. *et al.* Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B cell driven. *Am. J. Physiol. Gastrointest. Liver Physiol*. **300**, G833–G842 (2011).
35. Maresch, D. & Altmann, F. Isotype-specific glycosylation analysis of mouse IgG by LC-MS. *Proteomics*. **16**, 1321–1330 (2016).
36. Raju, T. S., Briggs, J. B., Borge, S. M. & Jones, A. J. S. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. *Glycobiology*. **10**, 477–486 (2000).
37. Mizuochi, T., Hamako, J. & Titani, K. Structures of the sugar chains of mouse immunoglobulin G. *Arch. Biochem. Biophys*. **257**, 387–394 (1987).
38. Mahan, A. E. *et al.* A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. *J. Immunol. Methods*. **417**, 34–44 (2015).
39. de Haan, N. *et al.* The N- glycosylation of Mouse immunoglobulin g ( IgG ) -Fragment crystallizable Differs Between IgG subclasses and strains. *Front Immunol*. **8**, 608 (2017).
40. Bowden, T. A. *et al.* Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. *J. Am. Chem. Soc*. **134**, 17554–17563 (2012).
41. Jefferis, R. & Lund, J. Interaction sites on human IgG-Fc for FcγR: Current models. *Immunol. Lett*. **82**, 57–65 (2002).
42. Pincetic, A. *et al.* Type I and type II Fc receptors regulate innate and adaptive immunity. *Nat. Immunol*. **15**, 707–716 (2014).
43. Subedi, G. P. & Barb, A. W. The Structural Role of Antibody N-Glycosylation in Receptor Interactions. *Structure* **23**, 1573–1583 (2015).
44. Quast, I., Peschke, B. & Lu, J. D. Regulation of antibody effector functions through IgG Fc N-glycosylation. *Cell Mol Life Sci*. **74**, 837–847 (2017).
45. Masuda, K. *et al.* Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. *Mol. Immunol*. **44**, 3122–3131 (2007).

46. Shields, R. L. *et al.* Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. *J. Biol. Chem.* **277**, 26733–26740 (2002).
47. Ferrara, C. *et al.* Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. *Proc. Natl. Acad. Sci.* **108**, 12669–12674 (2011).
48. Davies, J. *et al.* Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. *Biotechnol. Bioeng.* **74**, 288–294 (2001).
49. Shinkawa, T. *et al.* The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J. Biol. Chem.* **278**, 3466–3473 (2003).
50. Reusch, D. & Tejada, M. L. Fc glycans of therapeutic antibodies as critical quality attributes. *Glycobiology* **25**, 1325–1334 (2015).
51. Ahmed, A. *et al.* Structural characterization of anti-inflammatory Immunoglobulin G Fc proteins. *J Mol Biol.* **426**, 3166–3179 (2014).
52. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science.* **313**, 670–3 (2006).
53. Le, N. P. L., Bowden, T. A., Struwe, W. B. & Crispin, M. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. *Biochim. Biophys. Acta - Gen. Subj.* **1860**, 1655–1668 (2016).
54. Maverakis, E. *et al.* Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review. *J. Autoimmun.* **57**, 1–13 (2015).
55. Shade, K.-T. & Anthony, R. Antibody Glycosylation and Inflammation. *Antibodies* **2**, 392–414 (2013).
56. Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? *Nat. Rev. Immunol.* **13**, 176–189 (2013).
57. Anthony, R. M., Kobayashi, Toshihiko Wermeling, F. A. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel TH 2 pathway. *Nature* **475**, 110–113 (2013).
58. Anthony, R. M., Wermeling, F., Karlsson, M. C. I. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 19571–8 (2008).
59. Fiebiger, B. M., Maamary, J., Pincetic, A. & Ravetch, J. V. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. *Proc. Natl. Acad. Sci.* **12**, E2385-94 (2015).
60. Karsten, C. M. *et al.* Anti-inflammatory activity of IgG1 mediated by Fc

- galactosylation and association of FcγRIIB and dectin-1. *Nat Med.* **18**, 1401–1406 (2012).
61. Malhotra, R. *et al.* Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. *Nat. Med.* **1**, 237–243 (1995).
  62. Nimmerjahn, F., Anthony, R. M. & Ravetch, J. V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. *Proc Natl Acad Sci U S A.* **104**, 8433–8437 (2007).
  63. Boyd, P. N., Lines, A. C. & Patel, A. K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. *Mol. Immunol.* **32**, 1311–1318 (1995).
  64. Hodoniczky, J., Yuan, Z. Z. & James, D. C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. *Biotechnol. Prog.* **21**, 1644–1652 (2005).
  65. Dong, X., Storkus, W. J. & Salter, R. D. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. *J. Immunol.* **163**, 5427–5434 (1999).
  66. Goetze, A. M. *et al.* High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. *Glycobiology* **21**, 949–959 (2011).
  67. Jones, A. J. S. *et al.* Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. *Glycobiology* **17**, 529–540 (2007).
  68. Lee, S. J. *et al.* Mannose receptor-mediated regulation of serum glycoprotein homeostasis. *Science* **295**, 1898–1901 (2002).
  69. Banda, N. K. *et al.* Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. *Arthritis Rheum.* **58**, 3081–3089 (2008).
  70. Dashivets, T. *et al.* Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. *PLoS One* **10**, e0143520 (2015).
  71. Jensen, P. F. *et al.* Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. *Mol Cell Proteomics.* **14**, 148–61 (2015).
  72. van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. & Rombouts, Y. The Emerging Importance of IgG Fab Glycosylation in Immunity. *J. Immunol.* **196**, 1435–41 (2016).
  73. Bond, Alavi, A., Axford, J. S., Youinou, P. & Hay, F. C. The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS). *Clin. Exp. Immunol.* **105**, 99–103 (1996).

74. Kjeldsen-Kragh, J., Sumar, N., Bodman-Smith, K. & Brostoff, J. Changes in Glycosylation of IgG During Fasting in Patients with Rheumatoid Arthritis. *Rheumatology* **35**, 117–119 (1996).
75. Troelsen, L. N. *et al.* IgG glycosylation changes and MBL2 polymorphisms: Associations with markers of systemic inflammation and joint destruction in rheumatoid arthritis. *J. Rheumatol.* **39**, 463–469 (2012).
76. van de Geijn, F. E. *et al.* Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. *Arthritis Res. Ther.* **11**, R193 (2009).
77. Rombouts, Y. *et al.* Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. *Ann. Rheum. Dis.* **74**, 234–41 (2015).
78. Martin, K., Talukder, R., Hay, F. C. & Axford, J. S. Characterization of changes in IgG associated oligosaccharide profiles in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis using fluorophore linked carbohydrate electrophoresis. *J. Rheumatol.* **28**, 1531–1536 (2001).
79. Sjöwall, C. *et al.* Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. *Lupus* **24**, 569–81 (2014).
80. Vučković, F. *et al.* Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome. *Arthritis Rheumatol.* **67**, 2978–2989 (2015).
81. Dubé, R. *et al.* Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. *Gut* **31**, 431–4 (1990).
82. Trbojević Akmačić, I. *et al.* Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. *Inflamm. Bowel Dis.* **21**, 1237–47 (2015).
83. Yuan, S. *et al.* Changes in anti-thyroglobulin IgG glycosylation patterns in Hashimoto's thyroiditis patients. *J. Clin. Endocrinol. Metab.* **100**, 717–724 (2015).
84. Basset, C. *et al.* Changes in glycosylation of immunoglobulins in primary Sjögren's syndrome. *Ann Med Interne (Paris)*. **149**, 42–4 (1998).
85. Selman, M. H. J. *et al.* IgG Fc N-Glycosylation Changes in Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis research articles. *J. Proteome Res.* 143–152 (2011).
86. Lundström, S. L. *et al.* Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. *J. Alzheimer's Dis.* **38**, 567–579 (2014).
87. Wong, A. H. Y. *et al.* Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. *J. Neurol. Neurosurg. Psychiatry* **87**, 275–9 (2016).

88. Wuhrer, M. *et al.* Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. *J. neuroinflammation*. **12**, 235 (2015).
89. Ackerman, M. E. *et al.* Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. *J. Clin. Invest.* **123**, 2183–2192 (2013).
90. Gardinassi, L. G., Dotz, V., Ederveen, H., Almeida, P. De & Nery, H. Clinical Severity of Visceral Leishmaniasis Is Associated with Changes N-glycosylation, Immunoglobulin G Fc. **5**, 1–12 (2014).
91. Gunn, B. *et al.* Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. *Mucosal Immunol.* **9**, 1549–1558 (2016).
92. Ho, C. H. *et al.* Aberrant serum immunoglobulin g glycosylation in chronic hepatitis b is associated with histological liver damage and reversible by antiviral therapy. *J. Infect. Dis.* **211**, 115–124 (2015).
93. Mehta, A. S. *et al.* Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. *J. Virol.* **82**, 1259–70 (2008).
94. Moore, J. S. *et al.* Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. *AIDS* **19**, 381–389 (2005).
95. Aurer, I. *et al.* Aberrant glycosylation of Igg heavy chain in multiple myeloma. *Coll. Antropol.* **31**, 247–251 (2007).
96. Chen, G. *et al.* Change of fucosylated IgG2 Fc-glycoforms in pancreatitis and pancreatic adenocarcinoma: A promising disease-classification model. *Anal. Bioanal. Chem.* **406**, 267–273 (2014).
97. Chen, G. *et al.* Change in IgG1 Fc N-linked glycosylation in human lung cancer: Age- and sex-related diagnostic potential. *Electrophoresis* **34**, 2407–2416 (2013).
98. Chen, G. *et al.* Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. *J. Proteomics* **75**, 2824–2834 (2012).
99. Kanoh, Y. *et al.* Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression. *Anticancer Res* **26**, 4293–4297 (2006).
100. Kanoh, Y. *et al.* Changes in serum IgG oligosaccharide chains with prostate cancer progression. *Anticancer Res.* **24**, 3135–3139 (2004).
101. Kawaguchi-Sakita, N. *et al.* Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. *Biochem. Biophys. Res. Commun.* **469**, 1140–1145 (2016).
102. Kazuno, S. *et al.* Glycosylation status of serum immunoglobulin G in patients with prostate diseases. *Cancer Med.* **5**, 1137–46 (2016).

103. Kodar, K. *et al.* Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients. *World J. Gastroenterol.* **19**, 3573–3582 (2013).
104. Saldova, R. *et al.* Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. *Glycobiology.* **17**, 1344–1356 (2007).
105. Vučković, F. *et al.* IgG Glycome in Colorectal Cancer. *Clin. Cancer Res.* **22**, 1–10 (2016).
106. Zhang, D. *et al.* Disease-specific IgG Fc N-glycosylation as personalized biomarkers to differentiate gastric cancer from benign gastric diseases. *Sci. Rep.* **6**, 25957 (2016).
107. Stefanovic, G. *et al.* Hypogalactosylation of salivary and gingival fluid immunoglobulin G in patients with advanced periodontitis. *J. Periodontol.* **77**, 1887–1893 (2006).
108. Holland, M. *et al.* Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. *Clin. Exp. Immunol.* **129**, 183–190 (2002).
109. Einarsdottir, H. K. *et al.* Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. *Glycoconj. J.* **30**, 147–157 (2013).
110. Mahan, A. E. *et al.* Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. *PLoS Pathog.* **12**, 1–18 (2016).
111. Selman, M. H. J. *et al.* Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination. *Mol. Cell. Proteomics* **11**, M111.014563 (2012).
112. Vestrheim, A. C. *et al.* A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines. *Immunity, Inflamm. Dis.* **2**, 76–91 (2014).
113. Wang, J.-R. *et al.* Glycomic signatures on serum IgGs for prediction of postvaccination response. *Sci. Rep.* **5**, 7648 (2015).
114. Collins, E. S. *et al.* Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. *Rheumatol. (United Kingdom)* **52**, 1572–1582 (2013).
115. Wang, J. *et al.* Fc-glycosylation of IgG1 is modulated by B-cell stimuli. *Mol. Cell. Proteomics* **10**, M110.004655 (2011).
116. Prados, M. B., La Blunda, J., Szekeres-Bartho, J., Caramelo, J. & Miranda, S. Progesterone induces a switch in oligosaccharyltransferase isoform expression: Consequences on IgG N-glycosylation. *Immunol. Lett.* **137**, 28–37 (2011).
117. Kirkwood, T. B. L. A systematic look at an old problem. *Nature* **451**, 644–7 (2008).
118. López-Otín, C. *et al.* The Hallmarks of Aging. *Cell* **153**, 1194–1217 (2013).
119. Murabito, J. M., Yuan, R. & Lunetta, K. L. The Search for Longevity and Healthy Aging Genes : Insights From Epidemiological Studies and Samples of Long-Lived

- Individuals. *J Gerontol A Biol Sci Med Sci.* **67A**, 470–479 (2012).
120. Blair, S. N. *et al.* Physical Fitness and All-Cause Mortality. *JAMA.* **262**, 2395–2401 (1989).
  121. Fougère, B., Boulanger, E., Nourhashémi, F., Guyonnet, S. & Cesari, M. Chronic Inflammation : Accelerator of Biological Aging. *J Gerontol A Biol Sci Med Sci.* **72**, 1218–1225 (2017).
  122. Harman, D. The aging process. *Proc Natl Acad Sci U S A.* **78**, 7124–7128 (1981).
  123. Ladislav, R. Cellular and Molecular Mechanisms of Aging and Age Related Diseases. *Pathol Oncol Res.* **6**, 3–9 (2000).
  124. Sgarbieri, V. C. & Bertoldo Pacheco, M. T. Healthy human aging: intrinsic and environmental factors. *Braz. J. Food Technol.* **20**, e2017007 (2017).
  125. Vanhooren, V. & Libert, C. The mouse as a model organism in aging research: Usefulness, pitfalls and possibilities. *Ageing Res. Rev.* **12**, 8–21 (2013).
  126. Martini, F. *et al.* *Anatomy and Physiology.* (Rex Bookstore, Inc., 2007).
  127. Richardson, A. G. & Schadt, E. E. The Role of Macromolecular Damage in Aging and Age-related Disease. *J Gerontol A Biol Sci Med Sci.* **69**, S28–S32 (2014).
  128. Kaeberlein, M. Longevity and aging. *F1000Prime Rep.* **5**, 5 (2013).
  129. Kennedy, B. K. *et al.* Aging: a common driver of chronic diseases and a target for novel interventions. *Cell* **159**, 709–713 (2014).
  130. Engelfriet, P. M., Jansen, E. H. J. M., Picavet, H. S. J. & Dollé, M. E. T. Biochemical Markers of Aging for Longitudinal Studies in Humans. *Epidemiol. Rev.* **35**, 132–151 (2013).
  131. Jylhävä, J., Pedersen, N. L. & Hägg, S. Biological Age Predictors. *EBioMedicine* **21**, 29–36 (2017).
  132. Xia, X., Chen, W., Mcdermott, J. & Han, J. J. Molecular and phenotypic biomarkers of aging. *F1000Res.* **6**, 860 (2017).
  133. Lowsky, D. J., Olshansky, S. J., Bhattacharya, J. & Goldman, D. P. Heterogeneity in Healthy Aging. *J Gerontol A Biol Sci Med Sci.* **69**, 640–649 (2014).
  134. Bürkle, A. *et al.* MARK-AGE biomarkers of ageing. *Mech. Ageing Dev.* **151**, 2–12 (2015).
  135. Khan, S., Singer, B. & Vaughan, D. Molecular and physiological manifestations and measurement of aging in humans. *Ageing Cell* **16**, 624–633 (2017).
  136. Wiweko, B., Mustikaning, D. & Prawesti, P. Chronological age vs biological age : an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. *J Assist Reprod Genet.* **30**, 1563–1567 (2013).

137. Baker, G. T. & Sprott, R. L. Biomarkers of aging. *Exp Gerontol.* **23**, 223–239 (1988).
138. Carmona, J. J. & Michan, S. Biology of Healthy Aging and Longevity Biology of Healthy Aging and Longevity. *Rev Inves Clin.* **68**, 7–16 (2016).
139. Suzman, R. & Beard, J. Global Health and Aging. *National Institute of Aging, National Institute of Health and WHO* (2011).
140. He, W., Goodkind, D., Kowal, P. & Bureau, U. S. C. An Aging World : 2015 International Population Reports. *U.S. Government Publishing Office, Washington, DC* (2016).
141. American Federation for Aging Research AFAR. Biomarkers of aging. *American Federation for Aging Research* (2011).
142. Johnson, T. E. Recent results : Biomarkers of aging. *Exp Gerontol.* **41**, 1243–1246 (2006).
143. Lara, J. *et al.* A proposed panel of biomarkers of healthy ageing. *BMC Med.* **13**, 222 (2015).
144. Aubert, G. & Lansdorp, P. M. Telomeres and Aging. *Physiol Rev* **88**, 557–579 (2008).
145. Blackburn, E. H., Epel, E. S. & Lin, J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science* **350**, 1193–8 (2015).
146. Berglund, K. *et al.* Longitudinal decline of leukocyte telomere length in old age and the association with sex and genetic risk. *Aging (Albany NY)* **8**, 1398–1407 (2016).
147. Müezziner, A., Karina, A. & Brenner, H. A systematic review of leukocyte telomere length and age in adults. *Ageing Res. Rev.* **12**, 509–519 (2013).
148. Okuda, K. *et al.* Telomere Length in the Newborn. *Pediatr Res.* **52**, 377–381 (2002).
149. Slagboom, P. E., Droog, S. & Boomsma, D. Genetic Determination of Telomere Size in Humans : A Twin Study of Three Age Groups. *Am. J. Hum. Genet.* **55**, 876–882 (1994).
150. Lin, J., Epel, E. & Blackburn, E. Telomeres and lifestyle factors: roles in cellular aging. *Mutat Res.* **730**, 85–89 (2012).
151. Shamma, M. A. Telomeres, lifestyle, cancer, and aging. *Curr Opin Clin Nutr Metab Care.* **14**, 28–34 (2011).
152. Mather, K. A., Jorm, A. F., Parslow, R. A. & Christensen, H. Is Telomere Length a Biomarker of Aging ? A Review. *J Gerontol A Biol Sci Med Sci.* **66A**, 202–213 (2011).
153. Sanders, J. L. & Newman, A. B. Telomere Length in Epidemiology : A Biomarker of Aging , Age-Related Disease , Both , or Neither ? *Epidemiol Rev.* **35**, 112–131 (2013).
154. Sindi, S., Ngandu, T., Hovatta, I. & Ingemar, K. Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition : The FINGER Randomized



- Controlled Trial. *J. Alzheimer's Dis.* **59**, 1459–1470 (2017).
155. Aviv, A., Valdes, A. M. & Spector, T. D. Human telomere biology : pitfalls of moving from the laboratory to epidemiology. *Int J Epidemiol.* **35**, 1424–1429 (2006).
  156. Nordfjäll, K. *et al.* The Individual Blood Cell Telomere Attrition Rate Is Telomere Length Dependent. *PLoS Genet.* **5**, e1000375. (2009).
  157. Kirkwood, T. B. Understanding the Odd Science of Aging. *Cell* **120**, 437–447 (2005).
  158. Calado, R. T. & Dumitriu, B. Telomere dynamics in mice and humans. *Semin Hematol* **50**, 165–174 (2013).
  159. Mitchell, S. J., Scheibye-knudsen, M., Longo, D. L. & Cabo, R. De. Animal Models of Aging Research : Implications for Human Aging and. *Annu. Rev. Anim. Biosci.* **3**, 283–303 (2015).
  160. Yang, T.-L. B., Shufei, S. & Johnson, F. B. in *Handbook of the Biology of Aging* (eds. Kaeberlein, M. & Martin, G. M.) 205–241 (Academic Press, 2016).
  161. Blasco, M. Mice with bad ends : mouse models for the study of telomeres and telomerase in cancer and aging. *EMBO J* **24**, 1095–1103 (2005).
  162. Rudolph, K. L. *et al.* Longevity , Stress Response , and Cancer in Aging Telomerase-Deficient Mice. *Cell* **96**, 701–712 (1999).
  163. Jones, M. J., Goodman, S. J. & Michael, S. DNA methylation and healthy human aging. *Aging Cell* **14**, 924–932 (2015).
  164. Sen, P., Shah, P. P., Nativio, R. & Berger, S. L. Review Epigenetic Mechanisms of Longevity and Aging. *Cell* **166**, 822–839 (2016).
  165. Vinson, C. & Chatterjee, R. CG methylation. *Epigenomics* **4**, 655–663 (2012).
  166. Hannum, G., Guinney, J., Zhao, L., Zhang, L. & Hughes, G. Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. *Mol Cell.* **49**, 359–367 (2013).
  167. Horvath, S. DNA methylation age of human tissues and cell types DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, 3156 (2013).
  168. Chen, B. *et al.* DNA methylation - based measures of biological age : meta - analysis predicting time to death. *Aging (Albany NY).* **8**, 1844–1865 (2016).
  169. Christiansen, L. *et al.* DNA methylation age is associated with mortality in a longitudinal Danish twin study. *Aging Cell* **15**, 149–154 (2016).
  170. Marioni, R. E. *et al.* The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. *Int J Epidemiol.* **44**, 1388–1396 (2015).
  171. Zheng, Y. *et al.* Blood Epigenetic Age may Predict Cancer Incidence and Mortality. *EBioMedicine.* **5**, 68–73 (2016).

172. Stubbs, T. M. *et al.* Multi-tissue DNA methylation age predictor in mouse. *Genome Biol.* **18**, 68 (2017).
173. Belsky, D. *et al.* Eleven Telomere, Epigenetic Clock, and Biomarker-Composite Quantifications of Biological Aging: Do They Measure the Same Thing? *Am J Epidemiol.* (2017).
174. Marioni, R. E. *et al.* The epigenetic clock and telomere length are independently associated with chronological age and mortality. *Int J Epidemiol.* **45**, 424–432 (2016).
175. European Commission. ‘REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Seventh Report on the Statistics on the Number of Animals Used for Experimental and Other Scientific Purposes in the Member States of the European Union.’ (2013). at <Available from: <http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013DC0859>. Date of access: 11/08/2016>
176. Dutta, S. & Sengupta, P. Men and mice : Relating their ages. *Life Sci.* **152**, 244–248 (2016).
177. Demetrius, L. Aging in mouse and human systems: a comparative study. *Ann NY Acad Sci.* **1067**, 66–82 (2006).
178. Demetrius, L. Of mice and men. *EMBO Rep* **6**, S39–S44 (2005).
179. Hart, R. W. & Setlow, R. B. Correlation Between Deoxyribonucleic Acid Excision-Repair and Life-Span in a Number of Mammalian Species. *Proc Natl Acad Sci U S A.* **71**, 2169–2173 (1974).
180. Macrae, L. *et al.* DNA repair in species with extreme lifespan differences. *Aging (Albany NY)* **7**, 1171–1182 (2015).
181. Prowse, K. R. & Greider, C. W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. *Proc Natl Acad Sci U S A.* **92**, 4818–4822 (1995).
182. Tomás-Loba, A. *et al.* Telomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice. *Cell* **135**, 609–622 (2008).
183. Theodoris, C. V *et al.* Long telomeres protect against age-dependent cardiac disease caused by NOTCH1 haploinsufficiency. *J Clin Invest* **127**, 1683–1688 (2017).
184. Harper, J. M. Wild-derived mouse stocks: an underappreciated tool for aging research. *Age* **30**, 135–145 (2008).
185. Parekh, R., Roitt, I., Isenberg, D., Dwek, R. & Rademacher, T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. *J. Exp. Med.* **167**, 1731–6 (1988).
186. Tsuchiya, N. *et al.* Detection of glycosylation abnormality in rheumatoid IgG using N-acetylglucosamine-specific Psathyrella velutina lectin. *J Immunol.* **151**, 1137–46 (1993).


187. Yamada, E., Tsukamoto, Y., Sasaki, R., Yagyu, K. & Takahashi, N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. *Glycoconj. J.* **14**, 401–405 (1997).
188. Shikata, K. *et al.* Structural changes in the oligosaccharide moiety of human IgG with aging. *Glycoconj. J.* **15**, 683–689 (1998).
189. Selman, M. H. J. *et al.* Immunoglobulin G Glycopeptide Profiling by Matrix-Assisted Laser Desorption Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. *Anal Chem.* **82**, 1073–1081 (2010).
190. Ruhaak, L. R. *et al.* Decreased levels of bisecting GLcNAc glycoforms of IgG are associated with human longevity. *PLoS One* **5**, 1–8 (2010).
191. Westendorp, R. *et al.* Nonagenarian siblings and their offspring display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden Longevity Study. *J Am Geriatr Soc.* **57**, 1634–1637 (2009).
192. Pučić-Baković, M. *et al.* High-Throughput IgG Fc N-Glycosylation Profiling by Mass Spectrometry of Glycopeptides. *J Proteome Res.* **12**, 821–31 (2013).
193. Pučić, M. *et al.* Changes in plasma and IgG N-glycome during childhood and adolescence. *Glycobiology* **22**, 975–982 (2012).
194. Pezer, M. *et al.* Effects of allergic diseases and age on the composition of serum IgG glycome in children. *Sci. Rep.* **6**, 33198 (2016).
195. de Haan, N., Reiding, K., Driessen, G., van der Burg, M. & Wuhrer, M. Changes in Healthy Human IgG Fc-Glycosylation after Birth and during Early Childhood. *J Proteome Res.* **15**, 1853–61 (2016).
196. Ding, N. *et al.* Human serum N -glycan profiles are age and sex dependent. *Age Ageing.* **40**, 568–575 (2011).
197. Miura, Y., Hashii, N., Tsumoto, H., Takakura, D. & Ohta, Y. Change in N -Glycosylation of Plasma Proteins in Japanese Semisupercentenarians. *PLoS One.* **10**, e0142645 (2015).
198. Ruhaak, L. R. *et al.* Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health. *J. Proteome Res.* **10**, 1667–1674 (2011).
199. Vanhooren, V. *et al.* N-Glycomic Changes in Serum Proteins During. *Rejuvenation Res.* **10**, 521–531a (2007).
200. Vanhooren, V. *et al.* Serum N-glycan profile shift during human ageing. *Exp Gerontol.* **45**, 738–743 (2010).
201. Lemmers, R. F. H. *et al.* IgG glycan patterns are associated with type 2 diabetes in independent European populations. *Biochim Biophys Acta.* **1861**, 2240–2249 (2017).
202. Bodman, K. B. *et al.* IgG glycosylation in autoimmune-prone strains of mice. *Clin. Exp. Immunol.* **95**, 103–7 (1994).

203. Vanhooren, V. *et al.* Alteration in N-glycomics during mouse aging : a role for FUT8 Aging Cell. *Aging Cell.* **10**, 1056–1066 (2011).
204. Button, K. S. *et al.* Power failure: why small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci.* **14**, 365–76 (2013).
205. Ioannidis, J. P. A. Why Most Published Research Findings Are False. *PLoS Med.* **2**, e124 (2005).
206. Huffman, J. E. *et al.* Comparative Performance of Four Methods for High-throughput Glycosylation Analysis of Immunoglobulin G in Genetic and Epidemiological Research. *Mol Cell Proteomics.* **13**, 1598–610 (2014).
207. Seeling, M., Brückner, C. & Nimmerjahn, F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? *Nat Rev Rheumatol.* **13**, 621–630 (2017).
208. Jennewein, M. F. & Alter, G. The Immunoregulatory Roles of Antibody Glycosylation. *Trends Immunol.* **38**, 358–372 (2017).
209. Ercan, A. *et al.* Estrogens regulate glycosylation of IgG in women and men. *JCI Insight.* **2**, e89703 (2017).
210. Austad, S. Why Women Live Longer Than Men: Sex Differences in Longevity. *Genet Med.* **3**, 79–92 (2006).
211. Catera, M. *et al.* Identification of novel plasma glycosylation-associated markers of aging. *Oncotarget* **7**, 7455–7468 (2016).
212. Delves, P. J. *et al.* Polymorphism and expression of the galactosyltransferase-associated protein kinase gene in normal individuals and galactosylation-defective rheumatoid arthritis patients. *Arthritis Rheum.* **33**, 1655–1664 (1990).
213. Furukawa, K. *et al.* Kinetic study of a galactosyltransferase the B cells of patients with rheumatoid arthritis. *Int Immunol.* **2**, 105–12 (1990).
214. Jeddi, P. *et al.* Agalactosyl IgG and beta-1,4-galactosyltransferase gene expression in rheumatoid arthritis patients and in the arthritis-prone MRL lpr/lpr mouse. *Immunology.* **87**, 654–659 (1996).
215. Keusch, J., Lydyard, P. M., Berger, E. G. & Delves, P. J. B lymphocyte galactosyltransferase protein levels in normal individuals and in patients with rheumatoid arthritis. *Glycoconj J.* **15**, 1093–1097 (1998).
216. Axford, J. *et al.* Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. *Lancet* **2**, 1486–1488 (1987).
217. Keusch, J., Lydyard, P. M. & Delves, P. J. The effect on IgG glycosylation of altering  $\beta$  1, 4-galactosyltransferase-1 activity in B cells. *Glycobiology* **8**, 1215–1220 (1998).
218. Omtvedt, L. A. *et al.* Glycan analysis of monoclonal antibodies secreted in deposition disorders indicates that subsets of plasma cells differentially process IgG glycans.

- Arthritis Rheum.* **54**, 3433–3440 (2006).
219. Franceschi, C. *et al.* Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci.* **908**, 244–254 (2000).
220. Martinis, M. De, Franceschi, C., Monti, D. & Ginaldi, L. Inflamm-aging and lifelong antigenic load as major determinants of ageing rate and longevity. *FEBS Lett.* **579**, 2035–2039 (2005).
221. Chung, H. Y. *et al.* Molecular inflammation: underpinnings of aging and age-related diseases. *Ageing Res Rev.* **8**, 18–30 (2009).
222. Monti, D., Ostan, R., Borelli, V., Castellani, G. & Franceschi, C. Inflammaging and human longevity in the omics era. *Mech. Ageing Dev.* **165**, 129–138 (2016).
223. Dall’Olio, F. *et al.* N-glycomic biomarkers of biological aging and longevity : A link with inflammaging. *Ageing Res. Rev.* **12**, 685–698 (2013).
224. Weidner, C. I. *et al.* Aging of blood can be tracked by DNA methylation changes at just three CpG sites. *Genome Biol.* **15**, R24 (2014).
225. Churchill, G. a *et al.* The Collaborative Cross, a community resource for the genetic analysis of complex traits. *Nat. Genet.* **36**, 1133–1137 (2004).
226. Morahan, G., Balmer, L. & Monley, D. Establishment of ‘The Gene Mine’: A resource for rapid identification of complex trait genes. *Mamm. Genome.* **19**, 390–393 (2008).

## **8. APPENDICES**

**APPENDIX 1: Comparison of trends of change in the level of agalactosylated glycan GP4 with age among different strains of mice.**



**APPENDIX 2: Association between glycan traits and mouse age.**

<b>&lt; 80 weeks old</b>						
<b>Glycan</b>	<b>effect</b>	<b>DF</b>	<b>SE</b>	<b>p.val</b>	<b>p.adj</b>	<b>95% confidence intervals</b>
GP17b	-0,01385	417	0,002394	1,42E-08	8,20E-08	(-0.0186 - -0.0091)
GP6	-0,01339	417	0,002317	1,49E-08	8,20E-08	(-0.0179 - -0.0088)
GP17a	-0,00712	417	0,00222	0,001444	0,005294	(-0.0115 - -0.0028)
GP8	0,003495	417	0,002138	0,102763	0,282597	(-0.0007 - 0.0077)
GP20	-0,00288	417	0,002141	0,17892	0,360517	(-0.0071 - 0.0013)
GP9	-0,00364	417	0,002814	0,196646	0,360517	(-0.0092 - 0.0019)
GP14	0,001823	417	0,001852	0,325399	0,511341	(-0.0018 - 0.0055)
GP23	0,002062	417	0,002877	0,473861	0,651559	(-0.0036 - 0.0077)
GP1	0,001146	417	0,00231	0,619889	0,757642	(-0.0034 - 0.0057)
GP4	0,000391	417	0,001909	0,837958	0,858208	(-0.0034 - 0.0041)
GP25	0,000551	417	0,003084	0,858208	0,858208	(-0.0055 - 0.0066)
Sample size is n=494 biologically independent mice (75 CC strains)						
<b>≥20 to &lt;80 weeks old</b>						
<b>Glycan</b>	<b>effect</b>	<b>DF</b>	<b>SE</b>	<b>p.val</b>	<b>p.adj</b>	<b>95% confidence intervals</b>
GP23	0,012612	386	0,003452	2,94E-04	3,23E-03	(0.0058 - 0.0194)
GP17b	-0,00608	386	0,003031	4,56E-02	2,45E-01	(-0.0120 - -0.0001)
GP6	-0,00555	386	0,003019	6,68E-02	2,45E-01	(-0.0115 - 0.0004)
GP17a	-0,00458	386	0,002751	9,65E-02	2,51E-01	(-0.0100 - 0.0008)
GP25	0,006036	386	0,00385	1,18E-01	2,51E-01	(-0.0015 - 0.0136)
GP14	0,003476	386	0,002332	1,37E-01	2,51E-01	(-0.0011 - 0.0081)
GP8	-0,00335	386	0,002732	2,21E-01	3,47E-01	(-0.0087 - 0.0020)
GP4	-0,00145	386	0,002341	5,37E-01	5,72E-01	(-0.0060 - 0.0032)
GP1	0,001683	386	0,002856	5,56E-01	5,72E-01	(-0.0039 - 0.0073)
GP9	0,002076	386	0,00362	5,67E-01	5,72E-01	(-0.0050 - 0.0092)
GP20	0,001458	386	0,002576	5,72E-01	5,72E-01	(-0.0036 - 0.0065)
Sample size is n=461 biologically independent mice (73 CC strains)						



## **9. CURRICULUM VITAE**

Jasminka Krištić, maiden name Ilić, was born in Zabok (Croatia) on 22<sup>nd</sup> September 1987. She finished elementary school and gymnasium in Pregrada, Hrvatsko Zagorje. In 2006, she enrolled in the Molecular Biology programme at the Department of Biology, Faculty of Science, University of Zagreb, in the top 10 percent of students on the entrance exam. She graduated in 2011, first in her generation and with the highest grade.

After finishing her Master's in Molecular Biology, she worked shortly as a biology teacher, but soon after, she started to work at Genos Ltd., where she has been working for the past six years. As part of work on the international projects, she visited laboratories in Netherlands (Nijmegen) and Scotland (Edinburgh) for training and short-time research. In 2012, she started postgraduate doctoral programme at the Faculty of Science.

Jasminka Krištić has participated in numerous national and international conferences, meetings and workshops. She received the best poster award at the EMBO workshop on Glycobiology that took place in Lisbon, in 2014. Jasminka Krištić is the author of more than ten scientific papers, one of which was accompanied by editorial, two book chapters and several popular scientific articles in journals *Priroda*, *Adiva*, *Mamino sunce* and web portals *žena.hr* and *ZdravaKrava*. She is also a member of the Croatian Society of Biochemistry and Molecular Biology.

Jasminka Krištić, djevojačkog prezimena Ilić, rodila se 22. rujna 1987. godine u Zaboku (Hrvatska). Osnovnu školu i opću gimnaziju završila je u Pregradi, u Hrvatskom zagorju. 2006. godine upisala je studij molekularne biologije na Biološkom odsjeku Prirodoslovno-matematičkog fakulteta Sveučilišta u Zagrebu unutar 10% najboljih studenata na prijamnom ispitu. Diplomirala je 2011. godine prva u svojoj generaciji, s odličnim uspjehom.

Nakon završenog studija molekularne biologije, kratko je radila kao učiteljica biologije i prirode, da bi ubrzo počela raditi kao istraživač u Genos d.o.o., gdje radi već šest godina. U sklopu posla i rada na međunarodnim projektima, prošla je kratka usavršavanja u Nizozemskoj (Nijmegen) te Škotskoj (Edinburgh). Poslijediplomski doktorski studij biologije na Prirodoslovno-matematičkom fakultetu u Zagrebu upisala je 2012. godine.

Sudjelovala je na brojnim domaćim i međunarodnim kongresima, znanstvenim skupovima i simpozijima. U sklopu EMBO radionice u području glikobiologije, koja se održala 2014. godine u Portugalu (Lisabon), dobila je nagradu za najbolji poster. Autor je više od deset znanstvenih radova od kojih je jedan bio popraćen i editorijalom, dva poglavlja u knjigama te nekoliko znanstveno-popularnih članaka u časopisima Priroda, Adiva, Mamino sunce, te portalima žena.hr i ZdravaKrava. Članica je Hrvatskog društva za biokemiju i molekularnu biologiju.